Naphthylamide compound, and preparation method therefor and use thereof

MYPI2025003870A0Undetermined Publication Date: 2024-06-28SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003870
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-28
Filing Date
2023-12-27
Publication Date
2024-06-28

AI Technical Summary

Technical Problem

Existing Aurora B kinase inhibitors have relatively weak activity, and excessive VEGFR2 inhibition can lead to toxic side effects such as hypertension. Furthermore, they have difficulty crossing the blood-brain barrier, which limits their therapeutic effects on Aurora B kinase-related tumors and central nervous system diseases.

Method used

To develop a naphthamide compound with higher selectivity than VEGFR2, significant Aurora B kinase inhibitory activity and good blood-brain barrier penetration, for the treatment of diseases related to Aurora B kinase bioactivity.

Benefits of technology

This compound exhibits more significant inhibitory activity against Aurora B kinase at the cellular level, which can significantly inhibit tumor growth and achieve effective blood concentrations in brain tissue, providing a better overall benefit in terms of efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025003870_DRAWING_001
    Figure PI2025003870_DRAWING_001
Patent Text Reader

Abstract

A naphthylamide compound as represented by formula (I), a preparation method therefor, and the use thereof in the treatment and / or prevention of diseases related to the biological activity of the protein kinase.
Need to check novelty before this filing date? Find Prior Art

Description

A naphthamide compound, its preparation method and application Technical Field

[0001] The present invention belongs to the field of medicinal chemistry, and specifically relates to a naphthamide compound as a protein kinase inhibitor, a preparation method thereof, and its use in treating and / or preventing diseases related to the biological activity of the protein kinase. Background Art

[0002] Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor tyrosine kinases (RTKs) that include three structurally similar transmembrane protein members: VEGFR1 (also known as feline McDonough sarcoma (fms)-related tyrosine kinase-1, Flt-1), VEGFR2 (also known as kinase insert domain receptor (KDR)), and VEGFR3 (also known as Flt-4) (Moser C, et al., Clin. Colorectal Cancer., 2007, 6(8): 564-71). VEGFRs are expressed in endothelial cells, non-endothelial cells, including tumor cells. This type of receptor can bind to five natural ligands, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF (Placental Growth Factor). Among them, VEGF-A plays an irreplaceable role in the process of angiogenesis and maintenance, while VEGF-C and VEGF-D are ligands that mediate lymphangiogenesis. Among all receptors, VEGFR2 plays the most important role, being crucial in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis.

[0003] Because the diffusion limit of oxygen in mammalian tissue is approximately 100-200 μM, if the lack of new blood vessels to provide sufficient blood oxygen supply and the tumor relies solely on tissue diffusion, the growth diameter of metabolically active solid tumor tissue will be limited to 0.2-2.0 mm due to hypoxia. Therefore, anti-angiogenesis has become an effective treatment for various solid tumors (Adair TH, et al., Angiogenesis, Morgan & Claypool Life Sciences: San Rafael, CA, USA, 2010).

[0004] Currently, there are two main categories of approved drugs targeting tumor angiogenesis and the VEGF-VEGFRs pathway: one is monoclonal antibodies, such as bevacizumab, first approved in 2004, and ramucirumab, approved in 2014. The other is small molecule VEGFRs inhibitors, including sorafenib, axitinib, apatinib, sunitinib, regorafenib, vandetanib, pazopanib, lenvatinib, ponatinib, cabozantinib, and fruquintinib.

[0005] Anti-angiogenic drugs have greatly improved the treatment prospects of various solid tumors, but hypertension is one of the most common side effects of VEGF-VEGFRs inhibitors, and almost 100% of patients treated with these drugs experience elevated blood pressure. Studies have shown that hypertension caused by VEGF-VEGFRs inhibitors is a mechanism-dependent target toxicity, which often leads to dose adjustments or interruptions during treatment (Camarda N, et al., Curr. Oncol. Rep., 2022 Apr; 24(4): 463-74).

[0006] Aurora kinases (AURKs) are an important class of serine / threonine protein kinases that regulate the cell cycle. The human AURKs family includes three members: Aurora A, Aurora B, and Aurora C. In all somatic cells, only Aurora A and Aurora B are expressed at detectable levels (Tang A, et al., Oncotarget., 2017, 8:23937-54).

[0007] Aurora B is overexpressed in tumors of many different tissue origins relative to normal adjacent tissues. This kinase is encoded by the AURORA B gene located on chromosome 17 and is also known as AIK2, AIM1, ARK2, AIRK2, IPL1, STK1, STK5, and STK12. Its phosphorylation and modification of the Ser10 site of histone H3 is crucial for sister chromatid separation. Exogenous overexpression of Aurora B can increase the phosphorylation of histone H3 and chromosomal aneuploidy in normal cells, and injecting these Aurora B-overexpressing cells into BALB / c nu / nu mice can lead to tumor formation, indicating that Aurora B has a driving effect on tumorigenesis (Ota T, et al., Cancer Res., 2002, 62(18): 5168-77).

[0008] Inhibiting Aurora B as an anti-tumor target can block the abnormal connection between kinetochores and microtubules, preventing chromosome alignment and segregation, thereby triggering mitotic catastrophe and cell apoptosis. Furthermore, loss of Aurora B kinase activity can lead to cytokinesis failure, resulting in tetraploidy (or polyploidy). This severe genomic instability ultimately leads to cell death. Aurora B is expressed only in dividing and proliferating cells and is mostly stable in normal cells. Therefore, targeted inhibition of Aurora B is highly selective for actively dividing and proliferating tumor cells, offering significant advantages over other nonspecific cytotoxic drugs.

[0009] To date, no AURKs inhibitors have been approved for marketing worldwide, but clinical research on this type of inhibitors is currently active, including AURKs pan-inhibitors such as VX-680 / MK-0475 (Tozasertib), PHA-793358 (Danusertib), AT-9283, AMG 900, KW-2449, ABT-348 (Ilorasertib) and TT00420, Aurora A selective inhibitors such as MLN8237, ENMD 2076, VX-689 and LY3295668, and Aurora B selective inhibitors such as AZD1152 (Barasertib) and Chiauranib (Jing X, et al., Expert. Opin. Ther. Pat., 2021, 31(7): 625-44.). Existing evidence has shown to some extent that Aurora A or Aurora B selective inhibitors can avoid more toxicity than AURKs pan-inhibitors and therefore have better drugability.

[0010] Chiauranib is a small molecule inhibitor targeting multiple kinase pathways such as VEGFR, PDGFR, and Aurora B, developed by Shenzhen Chipscreen Biotech Co., Ltd. Clinical trials for tumor treatment are ongoing. According to the results of the Phase I clinical trial of Chiauranib, the dose-limiting toxicity (DLT) of Chiauranib occurred in the 65mg dosing group, manifested as grade 3 hypertension, which is a toxicity associated with VEGFR pathway inhibition. The recommended dose for Phase II clinical trials is 50mg. Under this dose condition, the drug is administered once a day, and the maximum blood drug exposure (C max ) is about 2.6 μM, and the steady-state blood drug exposure (C trough ) is about 1μM (Sun Y, et al., J. Hematol. Oncol., 2019, 12(1): 9.). The DLT of xioroni in humans is related to the inhibition of the VEGFR pathway, suggesting that the VEGFR pathway may be the dominant pathway for the in vivo efficacy of xioroni. According to in vitro cellular experiments, xioroni has relatively weak inhibitory activity against Aurora B kinase under 1-3μM conditions (equivalent to the drug exposure level in vivo), suggesting that there may be limited drug target mechanism in the treatment of Aurora B kinase-dependent tumors. Therefore, the development of multi-target kinase inhibitors with stronger selectivity for Aurora B kinase and relatively higher inhibition of Aurora B than VEGFR2 may achieve better efficacy against Aurora B kinase-dependent tumors within a similar human exposure and maximum tolerated dose (MTD) range.

[0011] Summary of the Invention

[0012] Problems to be solved by the invention:

[0013] Given that existing Aurora B kinase inhibitory activity is relatively weak, while overly potent VEGFR2 inhibitory activity can lead to toxic side effects such as hypertension, particularly when Aurora B kinase has low selectivity over VEGFR2, this limits the full efficacy of these drugs in treating tumors related to Aurora B kinase's biological activity. Furthermore, given the demanding requirements for treating primary and metastatic central nervous system tumors, therapeutic drugs must be able to cross the blood-brain barrier and achieve effective intracranial exposure to exert anti-tumor effects. Therefore, the present invention aims to provide compounds with enhanced selectivity for Aurora B kinase over VEGFR2. These compounds exhibit more pronounced inhibitory activity against Aurora B kinase at the cellular level at accessible plasma exposures, potentially achieving a better combination of efficacy and safety for related diseases. Furthermore, the compounds of the present invention possess excellent blood-brain barrier crossability and are suitable for the treatment and / or prevention of central nervous system diseases.

[0014] Solutions used to solve the problem:

[0015] In order to solve the above problems, the inventors of the present application conducted intensive research and found that naphthamide compounds with specific structures can achieve the desired purpose, resulting in the completion of the present invention.

[0016] The present invention relates to the following naphthamide compounds.

[0017] A compound represented by formula (I), or a stereoisomer, tautomer, polymorph, cocrystal, solvate, metabolite, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof:

[0018] in:

[0019] R 1 is selected from methyl or ethyl, said methyl or ethyl being unsubstituted or substituted by one or more identical or different R a replace;

[0020] Each R a are each independently selected from halogen, C 1-6 Alkoxy, -NR'R", halogenated C 1-6 Alkoxy; wherein R' and R" are each independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, or R' and R" together with the nitrogen atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, S;

[0021] R 2 and R 3 Each independently selected from: H, halogen, C 1-6 alkyl;

[0022] Ring A is selected from C 4-10 Cycloalkyl or 4-10 membered heterocyclic group; the 4-10 membered heterocyclic group contains 1 to 4 heteroatoms selected from N, O, S; the C 4-10 The cycloalkyl or 4-10 membered heterocyclic group is unsubstituted or substituted by one or more identical or different R b replace;

[0023] Each R b are each independently selected from halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0024] Alternatively, Ring A is selected from the group

[0025] in,

[0026] In A1, R 4 Selected from F, Cl, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0027] In A2, R 5 Selected from halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0028] In A3, R 4 and R 5 are each independently selected from halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0029] In A4, R 6 Selected from F or Cl, R 4 and R 5 are each independently selected from halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, when R 6 When it is Cl, R 1 is methyl or ethyl;

[0030] In A5, R 5 and R 6 are each independently selected from halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0031] Furthermore, when ring A is When R 1 is ethyl or is replaced by one or more R a substituted methyl or ethyl.

[0032] In some specific embodiments, R 1 Selected from methyl, ethyl; said methyl, ethyl is unsubstituted or substituted by 1, 2 or 3 identical or different R a replace.

[0033] In some embodiments, each R a are each independently selected from halogen, C 1-4 Alkoxy, -NR'R", halogenated C 1-4 Alkoxy; wherein R' and R" are each independently selected from H, C 1-4 Alkyl, C 3-5 Cycloalkyl, or R' and R" together with the nitrogen atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, and S.

[0034] In some embodiments, each Ra are each independently selected from halogen, C 5-6 Alkoxy, -NR'R", halogenated C 5-6 Alkoxy; wherein R' and R" are each independently selected from H, C 5-6 Alkyl, C 5-6 Cycloalkyl, or R' and R" together with the nitrogen atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, and S.

[0035] In some embodiments, each R a are each independently selected from halogen, C 1-3 Alkoxy, -NR'R", halogenated C 1-3 Alkoxy; wherein R' and R" are each independently selected from H, C 1-3 Alkyl, C 3-4 Cycloalkyl, or R' and R" together with the nitrogen atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, and S.

[0036] In some embodiments, each R a Each is independently selected from halogen, methoxy, ethoxy, propoxy, -NR'R", halogenated methoxy, halogenated ethoxy, halogenated propoxy; wherein R' and R" are each independently selected from H, methyl, ethyl, or R' and R" together with the N atom to which they are connected form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may additionally contain 1-2 heteroatoms selected from N, O, and S.

[0037] In some embodiments, each R a Each is independently selected from F, Cl, Br, methoxy, ethoxy, propoxy, -NR'R", halomethoxy, haloethoxy, halopropoxy; wherein R' and R" are each independently selected from H, methyl, ethyl, or R' and R" together with the N atom to which they are connected form a 4-7 membered nitrogen-containing heterocyclic group, which may further contain 1-2 heteroatoms selected from N, O, and S.

[0038] In some embodiments, each R a Each is independently selected from F, Cl, Br, methoxy, ethoxy, -NR'R", methoxy or ethoxy substituted by 1-3 F or Cl; wherein R' and R" are each independently selected from methyl, ethyl, or R' and R" together with the N atom to which they are connected form a 4-7 membered nitrogen-containing heterocyclic group, and the 4-7 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, and S.

[0039] In some embodiments, each Ra Each independently selected from F, Cl, methoxy, ethoxy, -NR'R", -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3; wherein R' and R" are each independently selected from methyl, ethyl, or R' and R" together with the N atom to which they are attached form

[0040] In some embodiments, each R a Each independently selected from F, Cl, methoxy, N,N-dimethylamino, N-methylamino, -OCHF2,

[0041] In some specific embodiments, R 1 Selected from methyl, ethyl, -CH2CH2F, -CH2CHF2, -CH2CH2Cl, methoxyethyl,

[0042] In some specific embodiments, when Ring A is When R 1 It is ethyl or -CH2CH2F.

[0043] In some specific embodiments, R 1 Selected from methyl and ethyl, wherein the methyl and ethyl groups are unsubstituted.

[0044] In some embodiments, Ring A is selected from C 4-7 Monocyclic alkyl, C 5-10 Spirobicycloalkyl, 4-7 membered monoheterocyclic group or 6-10 membered spirobicycloalkyl; the 4-7 membered monoheterocyclic group or 6-10 membered spirobicycloalkyl contains 1 to 4 heteroatoms selected from N, O, S, the C 4-7 Monocyclic alkyl, C 5-10 Spirobicycloalkyl, 4-7 membered monoheterocyclic group, 6-10 membered spirobicycloheterocyclic group is unsubstituted or substituted by 1, 2 or 3 identical or different R b replace.

[0045] In some embodiments, Ring A is selected from C 4-6 Monocyclic alkyl, C 6-8 Spiro bicycloalkyl, 4-7 membered monoheterocyclic group or 6-8 membered spiro bicycloheterocyclic group, wherein the 4-7 membered monoheterocyclic group or 6-8 membered spiro bicycloheterocyclic group contains 1 to 2 heteroatoms selected from N, O, S, and the C 4-6 Monocyclic alkyl, C 6-8 Spirobicycloalkyl, 4-7 membered monoheterocyclic group, 6-8 membered spirobicycloheterocyclic group is unsubstituted or substituted by 1, 2 or 3 identical or different R b replace.

[0046] In some embodiments, Ring A is selected from described is unsubstituted or replaced by 1, 2 or 3 identical or different R b replace.

[0047] In some embodiments, each R b are each independently selected from halogen, C 1-6 alkyl.

[0048] In some embodiments, each R b Each independently selected from F, Cl, Br, C 1-4 Alkyl, C 5-6 alkyl.

[0049] In some embodiments, each R b Each is independently selected from F, Cl, Br, methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl.

[0050] In some embodiments, each R b Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, and sec-butyl.

[0051] In some embodiments, each R b Each is independently selected from F, Cl, Br, and methyl.

[0052] In some embodiments, each R b are each independently selected from F.

[0053] In some embodiments, Ring A is selected from

[0054] In some specific embodiments, in A1, R 4 Selected from F, Cl, C 1-4 Alkyl, C 5-6 Alkyl, halogenated C 1-4 Alkyl, halogenated C 5-6 alkyl.

[0055] In some specific embodiments, in A1, R 4 Selected from F, Cl, C 1-4 Alkyl, halogenated C 1-4 alkyl.

[0056] In some specific embodiments, in A1, R 4 Selected from F, Cl, methyl, ethyl, propyl, isopropyl, C 1-4Alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl.

[0057] In some specific embodiments, in A1, R 4 Selected from F, Cl, methyl, ethyl, methyl substituted by fluorine or chlorine, ethyl substituted by fluorine or chlorine.

[0058] In some specific embodiments, in A1, R 4 Selected from F, Cl, methyl.

[0059] In some specific embodiments, in A2, R 5 Selected from F, Cl, Br, C 1-4 Alkyl, C 5-6 Alkyl, halogenated C 1-4 Alkyl, halogenated C 5-6 alkyl.

[0060] In some specific embodiments, in A2, R 5 Selected from F, Cl, Br, C 1-4 Alkyl, halogenated C 1-4 alkyl.

[0061] In some specific embodiments, in A2, R 5 Selected from F, Cl, Br, C 5-6 Alkyl, halogenated C 5-6 alkyl.

[0062] In some specific embodiments, in A2, R 5 Selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl.

[0063] In some specific embodiments, in A2, R 5 Selected from F, Cl, Br, methyl, ethyl, methyl substituted by fluorine or chlorine, ethyl substituted by fluorine or chlorine.

[0064] In some specific embodiments, in A2, R 5 Selected from F, Cl, Br, methyl.

[0065] In some specific embodiments, in A2, R 5 Selected from F.

[0066] In some specific embodiments, in A3, R 4 and R 5 are each independently selected from halogen, C 1-4 Alkyl, C 5-6 Alkyl, halogenated C 1-4 Alkyl, halogenated C 5-6 alkyl.

[0067] In some specific embodiments, in A3, R 4 and R 5 Each independently selected from F, Cl, Br, C 1-4 Alkyl, halogenated C 1-4 alkyl.

[0068] In some specific embodiments, in A3, R 4 and R 5 Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, and haloC4 alkyl.

[0069] In some specific embodiments, in A3, R 4 and R 5 Each is independently selected from F, Cl, Br, methyl, ethyl, fluoro- or chloro-substituted methyl, fluoro- or chloro-substituted ethyl.

[0070] In some specific embodiments, in A3, R 4 and R 5 are each independently selected from F or Cl.

[0071] In some specific embodiments, in A3, R 4 F, R 5 is F or Cl.

[0072] In some embodiments, Ring A is selected from

[0073] In some specific embodiments, in A4, R 6 Selected from F or Cl, R 4 and R 5 are each independently selected from halogen, C 1-4 Alkyl, C 5-6 Alkyl, halogenated C 1-4 Alkyl, halogenated C 5-6 Alkyl, when R 6 When it is Cl, R 1 It is methyl or ethyl.

[0074] In some specific embodiments, in A4, R 6 Selected from F or Cl, R 4 and R 5 Each independently selected from F, Cl, Br, C 1-4 Alkyl, halogenated C 1-4 Alkyl; when R 6 When it is Cl, R 1 It is methyl or ethyl.

[0075] In some specific embodiments, in A4, R 6 Selected from F or Cl, R 4 and R 5 Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl; when R 6 When it is Cl, R 1 It is methyl or ethyl.

[0076] In some specific embodiments, in A4, R 6 Selected from F or Cl, R 4 and R 5 are each independently selected from F, Cl, Br, methyl, ethyl, methyl substituted with fluorine or chlorine, ethyl substituted with fluorine or chlorine; when R 6 When it is Cl, R 1 It is methyl or ethyl.

[0077] In some specific embodiments, in A4, R 6 Selected from F or Cl, R 4 and R 5 Each independently selected from F or Cl; when R 6 When it is Cl, R 1 It is methyl or ethyl.

[0078] In some specific embodiments, in A5, R 5 and R 6 are each independently selected from halogen, C 1-4 Alkyl, C 5-6 Alkyl, halogenated C 1-4 Alkyl, halogenated C 5-6 alkyl.

[0079] In some specific embodiments, in A5, R 5 and R 6 Each independently selected from F, Cl, Br, C 1-4 Alkyl, halogenated C 1-4 alkyl.

[0080] In some specific embodiments, in A5, R 5 and R 6 Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, and haloC4 alkyl.

[0081] In some specific embodiments, in A5, R 5 and R 6 Each is independently selected from F, Cl, Br, methyl, ethyl, fluoro- or chloro-substituted methyl, fluoro- or chloro-substituted ethyl.

[0082] In some specific embodiments, in A5, R 5 and R 6 are each independently selected from F or Cl.

[0083] In some embodiments, Ring A is selected from

[0084] In some embodiments, Ring A is selected from

[0085] When ring A is selected from When R 1 It is methyl or ethyl.

[0086] In some embodiments, Ring A is selected from

[0087] In some embodiments, Ring A is selected from

[0088] In some embodiments, Ring A is selected from

[0089] In some embodiments, Ring A is selected from

[0090] In some embodiments, Ring A is selected from

[0091] In some embodiments, Ring A is selected from R 1 It is ethyl or -CH2CH2F.

[0092] In some embodiments, Ring A is selected from R 1 It is ethyl or -CH2CH2F.

[0093] In some embodiments, Ring A is selected from

[0094] In some embodiments, Ring A is selected from

[0095] In some embodiments, Ring A is selected from

[0096] In some embodiments, Ring A is selected from

[0097] In some embodiments, Ring A is selected from

[0098] In some embodiments, Ring A is selected from R 1 It is methyl or ethyl.

[0099] In some embodiments, Ring A is selected from R 1 It is methyl or ethyl.

[0100] In some specific embodiments, R 2 and R 3 are each independently selected from H, halogen, C 1-4 Alkyl, C 5- 6 alkyl.

[0101] In some specific embodiments, R 2 and R 3 Each is independently selected from H, F, Cl, Br, methyl, ethyl, propyl, isopropyl, butyl, pentyl, and hexyl.

[0102] In some specific embodiments, R 2 and R 3 Each is independently selected from H, F, Cl, and Br.

[0103] In some specific embodiments, R 2 and R 3 Each is independently selected from H and F.

[0104] In some specific embodiments, R 2 and R 3 At the same time, it is H.

[0105] In some specific embodiments, R 2 and R 3 One of them is H and the other is F.

[0106] In some specific embodiments, R 2 H, R 3 For F.

[0107] In some specific embodiments, R 2 F, R 3 For H.

[0108] In some specific embodiments, the above compound is selected from:

[0109] As used herein, examples of the term "pharmaceutically acceptable salt of the compound represented by formula (I)" are organic acid addition salts formed with organic acids that form pharmaceutically acceptable anions.

[0110] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, prepared by reacting the compounds discovered herein with the specified substituents with relatively nontoxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the compounds with a sufficient amount of base in neat solution or in a suitable inert solvent. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.

[0111] The term "prodrug" refers to derivatives of the compound represented by formula (I) with specific substituents discovered in the present invention. They themselves may have weak activity or even no activity, but after administration, they are converted into the compound with specific substituents discovered in the present invention under physiological conditions (for example, by metabolism, solvent decomposition or other means) and produce corresponding biological activity in the body.

[0112] The term "metabolite" refers to a product obtained by in vivo metabolism of a compound of formula (I) having specific substituents discovered by the present invention. Metabolites of a compound can be identified by techniques known in the art, and their activity can be characterized by assays as described herein. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of the compound, including metabolites produced by contacting the compound of the present invention with a mammal for a sufficient period of time.

[0113] The term "deuterated compound" refers to a compound of the present invention that includes at least one deuterium atom, specifically one or more hydrogen atoms in a compound of the present invention that can be replaced or substituted with a deuterium atom. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 deuterium atoms. Synthetic methods for incorporating isotopes into organic compounds are known in the art.

[0114] When the structural formula of the compound of general formula (I) of the present invention is inconsistent with the Chinese name, the structural formula shall prevail.

[0115] Preparation method:

[0116] Therefore, another aspect of the present invention also provides the preparation method of the above-mentioned compound according to the present invention. The preparation of the compound described in general formula (I) of the present invention can be completed by the following illustrative methods and examples, but these methods and examples should not be considered to limit the scope of the present invention in any way. The compound described in the present invention can also be synthesized by synthetic techniques known to those skilled in the art, or a combination of synthetic methods known in the art and the method described in the present invention can be used. The product obtained by each step of the reaction is obtained using separation techniques known in the art, including but not limited to extraction, filtration, distillation, crystallization, chromatographic separation, etc. The starting materials and chemical reagents required for the synthesis can be synthesized according to conventional literature (such as provided by Scifinder) or purchased.

[0117] The following synthetic routes describe methods for preparing compounds of formula (I) of the present invention. The starting materials, reagents, catalysts, solvents, etc. used in the following synthetic schemes can be prepared by methods well known to those skilled in the art of organic chemistry or are commercially available. All final derivatives of the present invention can be prepared by the methods described in the schemes or analogous methods thereof, which are well known to those skilled in the art of organic chemistry. All variables used in these schemes are as defined above and below.

[0118] Preparation method

[0119] The definitions of the following variables are as described above, while new variable definitions are as described in this section. In addition, the compounds described in general formula (I) and the intermediates involved can be purified by common separation methods, such as extraction, recrystallization, and silica gel column chromatography. The 200-300 mesh silica gel and thin layer chromatography silica gel plates used were all produced by Qingdao Ocean Chemical Plant. The chemical reagents used were commercially available analytical or chemically pure products of general reagents and were not further purified when used.

[0120] The present invention provides a method for preparing a compound represented by general formula (I), comprising the following steps:

[0121] 1) The compound represented by formula (Ia) is reacted with the compound represented by formula (Ib) in a first solvent, catalyzed by a first base, to obtain the compound represented by formula (Ic) through a nucleophilic substitution reaction; or the compounds represented by formula (Ia) and formula (Ib) can also obtain the compound represented by formula (Ic) through a Mitsunobu reaction in the presence of triphenylphosphine (PPh3) / diethyl azodiacid (DEAD) or triphenylphosphine (PPh3) / diisopropyl azodiacid (DIAD);

[0122] 2) reacting the compound represented by formula (Ic) with the compound represented by formula (Id) in a second solvent under the action of a second base to obtain the compound represented by formula (Ie) through a nucleophilic substitution reaction;

[0123] 3) The compound represented by formula (Ie) and the compound represented by formula (If) undergo condensation reaction in a third solvent under the action of a condensing agent and a third base to obtain a compound represented by formula (I).

[0124] in:

[0125] R 1 、R 2 、R 3 , Ring A is defined as above;

[0126] X is selected from bromine, iodine, -OMs, -OTf, -OTs, -OH.

[0127] In some embodiments, in step 1), the first solvent is selected from dichloromethane (DCM), 1,2-dichloroethane, 1,4-dioxane, tetrahydrofuran (THF), acetonitrile (MeCN), N,N'-dimethylformamide (DMF), N-methylpyrrolidone (NMP) or a combination thereof.

[0128] In some embodiments, in step 1), the first base is selected from potassium carbonate (K2CO3), cesium carbonate (Cs2CO3) or a combination thereof.

[0129] In some embodiments, in step 2), the second solvent is selected from 1,2-dichloroethane, 1,4-dioxane, tetrahydrofuran (THF), acetonitrile (MeCN), N,N'-dimethylformamide (DMF), N-methylpyrrolidone (NMP), isopropanol, N,N'-dimethylsulfoxide (DMSO) or a combination thereof.

[0130] In some embodiments, in step 2), the second base is selected from potassium carbonate (K2CO3), cesium carbonate (Cs2CO3), diisopropylethylamine (DIEA) or a combination thereof.

[0131] In some embodiments, in step 3), the condensing agent is selected from 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl), 1-hydroxybenzotriazole (HOBt), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (TCFH) and N-methylimidazole, among which TCFH is particularly suitable for the condensation of larger sterically hindered amines, 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (PyBOP) or a combination thereof.

[0132] In some embodiments, in step 3), the third solvent is selected from dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), acetonitrile (MeCN), N,N'-dimethylformamide (DMF), or a combination thereof.

[0133] In some embodiments, the third base is selected from triethylamine (TEA) and diisopropylethylamine (DIEA).

[0134] Pharmaceutical composition:

[0135] The present invention also provides a pharmaceutical composition comprising any of the aforementioned compounds, or their stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, and optional pharmaceutical carriers and / or adjuvants and / or diluents.

[0136] In some embodiments, the pharmaceutical composition may further comprise other drugs for treating and / or preventing diseases associated with the biological activity of Aurora B kinase.

[0137] Methods for preparing various pharmaceutical compositions containing a certain amount of active ingredient are known or will be apparent to those skilled in the art based on the disclosure of the present invention. As described in REMINGTON'S PHARMACEUTICAL SCIENCES, Martin, EW, ed., Mack Publishing Company, 19th ed. (1995), the method for preparing the pharmaceutical composition includes incorporating appropriate pharmaceutical excipients, carriers, diluents, etc.

[0138] Medical uses:

[0139] Another aspect of the present invention relates to the above-mentioned compounds according to the present invention, or their stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, and compositions thereof, for use in treating and / or preventing diseases associated with the biological activity of Aurora B kinase.

[0140] Another aspect of the present invention relates to the use of the above-mentioned compounds according to the present invention, or their stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, and compositions thereof, in the preparation of medicaments for treating and / or preventing diseases associated with the biological activity of Aurora B kinase.

[0141] A method for treating and / or preventing a disease associated with the biological activity of Aurora B kinase, comprising administering to a subject in need thereof a therapeutically / preventively effective amount of the above-mentioned compound, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, or combinations thereof.

[0142] According to a preferred embodiment of the present invention, the disease associated with the biological activity of Aurora B kinase is selected from tumors or hyperproliferative diseases.

[0143] In the present invention, "treatment" refers to the administration of a drug or other adjunctive therapy to a subject in order to obtain the desired pharmacological and / or physiological effect. The effect may be prophylactic, based on the complete or partial prevention of a disease or its symptoms; and / or therapeutic, based on the partial or complete stabilization or cure of a disease and / or the side effects caused by the disease. As used herein, "treatment" encompasses any treatment of a patient's disease, including: (a) preventing the disease or symptoms from occurring in a patient who is susceptible to the disease or symptoms but has not yet been diagnosed with the disease; (b) suppressing the symptoms of the disease, i.e., preventing its development; or (c) alleviating the symptoms of the disease, i.e., causing the disease or symptoms to regress.

[0144] In the present invention, "subject" refers to a vertebrate. In certain embodiments, the vertebrate refers to a mammal. Mammals include, but are not limited to, livestock (such as cattle), pets (such as cats, dogs, and horses), primates, mice, and rats. In certain embodiments, the mammal refers to a human.

[0145] In the present invention, an "effective amount" refers to an amount that is effective at the necessary dosage and time to achieve the desired therapeutic or preventive effect. The "therapeutically effective amount" of the substance / molecule of the present invention may vary according to factors such as the disease state, age, sex and weight of the individual and the ability of the substance / molecule to elicit the desired response in the individual. A therapeutically effective amount also encompasses an amount in which the therapeutically beneficial effects of the substance / molecule outweigh any toxic or deleterious consequences. A "prophylactically effective amount" refers to an amount that is effective at the necessary dosage and time to achieve the desired preventive effect. Typically, but not necessarily, a prophylactic dose is used in subjects before the onset of disease or in the early stages of the disease, so the prophylactic effective amount will be lower than the therapeutically effective amount. In the case of cancer, a therapeutically effective amount of a drug can reduce the number of cancer cells; reduce tumor size; inhibit (i.e., slow down to a certain extent, preferably stop) cancer cell infiltration into surrounding organs; inhibit (i.e., slow down to a certain extent, preferably stop) tumor metastasis; inhibit tumor growth to a certain extent; and / or alleviate one or more symptoms associated with cancer to a certain extent.

[0146] Definition of terms:

[0147] According to the common practice in this field, The bonds used in the formulae herein to describe the points of attachment of the moiety or substituent to the parent core or structure.

[0148] A dash "-" that does not appear between two letters or symbols is used to indicate the point of attachment of a substituent. For example, -NR'R" is attached through the N atom.

[0149] In various parts of this specification, substituents of compounds disclosed herein are disclosed in terms of group types or ranges. It is specifically noted that the present invention includes every independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl disclosed independently, or "C 1-4 Alkyl", or independently disclosed "C 1-3 alkyl".

[0150] The term "alkyl" as used herein refers to a saturated aliphatic hydrocarbon group including both branched and straight chain groups having a specified number of carbon atoms. For example, "C1-6 alkyl" refers to C1, C2, C3, C4, C5, and C6. In addition, for example, "C 1- "6-alkyl" refers to an alkyl group having 1 to 6 carbon atoms. The alkyl group may be unsubstituted or substituted so that one or more of its hydrogen atoms are replaced by another chemical group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like.

[0151] The term "alkoxy" refers to any of the above alkyl groups (eg, C1-6 alkyl, C1-4 alkyl, C1-3 alkyl, etc.) that is attached to the rest of the molecule through an oxygen atom (-O-).

[0152] The term "halogenated C 1-6 Alkyl" or "halogenated C 1-6 "Alkoxy" refers to an alkyl or alkoxy group in which one or more (such as 2 or 3) hydrogen atoms are replaced by halogen atoms, such as fluorine, chlorine, bromine, or iodine. The alkyl or alkoxy group is defined as above. In some embodiments, the term "halogenated C 1-6 "Alkyl" is preferably fluorinated or chlorinated, for example, -CF3, -CHF2, -CH2F, -CH2CH2F, -CH2CH2Cl, -CH2CHF2, -CH2CF3, etc. In some embodiments, the term "halogenated C 1-6 The "alkoxy" is preferably fluorinated, for example, it can be -OCF3, -OCHF2, -OCH2F, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, etc.

[0153] As used herein, the term "substituted" means that any one or more hydrogens on a designated atom or group are replaced with the selection of a designated group, provided that the normal valence of the designated atom is not exceeded.

[0154] The term "cycloalkyl" refers to a cyclized alkyl group, including monocyclic, bicyclic or polycyclic ring systems. When the cycloalkyl group is bicyclic or polycyclic, each ring should be a saturated carbocyclic ring or a carbocyclic ring residue. The two rings of the bicyclic or polycyclic cycloalkyl group can be connected in a manner including bridging, fusion or spiro connection. For example, C 3-10 Cycloalkyl refers to C3, C4, C5, C6, C7, C8, C9 and C 10 Cycloalkyl. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0155] The term "carbocycle" or "carbocycle residue" refers to any stable 3-, 4-, 5-, 6- or 7-membered monocyclic ring or 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered bicyclic or polycyclic ring, any one of which may be saturated, partially saturated, unsaturated or aromatic. The bicyclic or polycyclic carbocycles may be connected in a manner such as bridging, fusion or spiro. Examples of these carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptenyl, cycloheptyl, adamantyl, cyclooctyl, phenyl, naphthyl, [2,2,2]bicyclooctane, wait.

[0156] The terms "heterocycle", "heterocyclic" or "heterocyclyl" are used interchangeably and refer to substituted and unsubstituted 4-8 membered monocyclic or bicyclic groups, 8-10 membered bicyclic or tricyclic groups and 10-14 membered tricyclic or polycyclic groups, wherein at least one ring has at least one heteroatom (O, S or N), preferably the heteroatom-containing ring has 1, 2 or 3 heteroatoms selected from O, S and N. Each heteroatom-containing ring in the group may contain 1 or 2 oxygen or sulfur atoms and / or 1 to 4 nitrogen atoms, provided that the total number of heteroatoms in each ring is 4 or less, and further provided that the ring contains at least one carbon atom. In some preferred embodiments, the heteroatom refers only to N or O, and the total number does not exceed 3, preferably only 1-2 heteroatoms. The fused rings of the group may contain only carbon atoms and may be saturated, partially saturated or fully unsaturated, aromatic or non-aromatic. The heterocyclic group may be attached at any available nitrogen or carbon atom. As used herein, "heterocycle" does not include a completely aromatic ring.

[0157] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0158] The term "heteroatom" shall include oxygen, sulfur and nitrogen.

[0159] The term "XXX is unsubstituted or substituted with one or more identical or different YYY" means that XXX may be unsubstituted or substituted with YYY. Substituted with one or more YYY means that XXX may be substituted with one YYY (i.e., with only one substituent YYY) or with multiple substituents YYY, with each YYY being independently selected from a substituent group within the corresponding range and being substituted at any substitutable position. A plurality of substituents is 2 or more, preferably 2, 3, or 4, and more preferably 2 or 3.

[0160] Throughout the specification, groups and substituents thereof may be chosen by one skilled in the art to provide stable moieties and compounds and compounds useful as pharmaceutically acceptable compounds and / or intermediate compounds useful in preparing pharmaceutically acceptable compounds.

[0161] Effects of the invention:

[0162] The naphthamide compounds of the specific structure of formula (I) of the present invention exhibit excellent Aurora B kinase inhibitory activity, with higher Aurora B kinase inhibitory selectivity relative to VEGFR2, and have a certain impact on the tumor cell cycle, which can achieve a better efficacy and safety combination for related diseases. Furthermore, in brain penetration testing, the ratio of the compound concentration in brain tissue to the plasma concentration of the compound of the present invention was significantly higher than that of the control molecules 01 (Chiauranib) and 02. This test result indicates that the compound of the present invention has excellent brain barrier permeability, can cross the blood-brain barrier, and has the potential to achieve effective blood drug concentrations in brain tissue, and can be used to treat and prevent central nervous system-related diseases. In addition, in antitumor efficacy experiments in mice, the compound of the present invention significantly reduced tumor volume and significantly improved tumor volume inhibition rate compared to the control molecules 01 and 02. This experimental result indicates that the compound of the present invention has excellent in vivo antitumor efficacy and can significantly inhibit tumor growth. Description of the drawings:

[0163] Figure 1 represents the changes in subcutaneous tumor volume of mice in each group during treatment with compound I-9 of the present invention, control molecule 01 (Chiauranib), and control molecule 02. The vertical axis is the average tumor volume (mm 3 ), the horizontal axis is the number of treatment days after grouping (days). DETAILED DESCRIPTION

[0164] The examples and preparations provided herein further illustrate and illustrate the compounds of the present invention and their preparation methods. It should be understood that the following preparations and examples do not limit the scope of the present invention in any way.

[0165] It should be understood that the terminology used herein is intended to describe specific embodiments and is not intended to be limiting. In addition, although any method, device, and material similar or equivalent to those described herein may be used for implementing or testing the present invention, preferred methods, devices, and materials are now described.

[0166] LC-MS analysis method:

[0167] Mass spectrometry conditions: instrument: Thermo ISQ EC; ion source: ESI (EA+EA-); source temperature: 300°C; sheath gas pressure: 50.0 psi; auxiliary gas pressure: 5.0 psi; purge gas pressure: 0.5 psi; vaporizer temperature: 300°C.

[0168] Chromatographic conditions: instrument Thermo U3000; detector DAD-3000(RS) (diode array detector); chromatographic column Phenomenon Titank C18 3μm 4.6×50mm; flow rate 2.0mL / min, split; column temperature 35°C; mobile phase A contained 0.05% formic acid and 5% acetonitrile in water; mobile phase B contained 0.05% formic acid in acetonitrile; elution method: linear elution from 100% to 5% phase A within 0-1.0min, followed by a 1.2min hold at 5% phase A.

[0169] HPLC analysis method:

[0170] Instrument: Thermo U3000; detector: VWD-3×00(RS) (UV detector); wavelength: 254 nm; chromatographic column: Shimadzu inertsil 3 μm, 4.6×150 mm; flow rate: 0.8 mL / min; column temperature: 35°C; mobile phase A: 0.05% formic acid and 5% acetonitrile in water; mobile phase B: 0.05% formic acid in acetonitrile; elution method: first hold 100% of phase A for 1.0 min, then linearly elute phase A from 100% to 5% within 1.0 to 8.0 min, and finally hold 5% phase A for 4.0 min.

[0171] 1 H-NMR analysis method:

[0172] 1 H-NMR measurements were performed at room temperature using a BRUKER AVANCE-400 MHz NMR spectrometer in DMSO-d₆ or CDCl₃, using TMS as the internal standard. Signal peaks are represented as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (double of doublets), and tt (double of triplets). Coupling constants (J) are reported in Hertz (Hz).

[0173] According to the above-described method, the present invention prepared representative compounds I-1 to I-44 (see Table 1) and tested and recorded their purity. Among them, five compounds (I-7, I-11, I-12, I-13 and I-14) were used as control compounds.

[0174] Table 1

[0175] The present invention will be further described below in conjunction with specific examples, but the scope of protection of the present invention is not limited to these examples. Percentages described in the present invention are all weight percentages unless otherwise specified. The numerical ranges described in the specification, such as unit of measurement, reaction conditions, physical state of the compound or percentage, are all for the purpose of providing unambiguous written references. Those skilled in the art, when implementing the present invention, may still obtain the expected results by using temperature, concentration, quantity, carbon number, etc. outside this range or different from a single numerical value. In addition, the raw materials in the following examples, unless otherwise specified, are commercially available, for example, can be purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd., Jiangsu Aikang Biopharmaceutical R&D Co., Ltd., Nanjing Yaoshi Technology Co., Ltd., Shanghai Shaoyuan Reagent Co., Ltd., and Hechun Biotechnology (Shanghai) Co., Ltd.

[0176] Preparation of intermediate: I-1c

[0177] Commercially available I-1a (2.0 g, 11.13 mmol, 1.0 eq) was dissolved in DMF (30 mL), and Cs2CO3 (10.88 g, 33.39 mmol, 3.0 eq) and I-1b (3.64 g, 33.39 mmol, 3.0 eq) were added. The mixture was stirred at room temperature for 3 hours. The reaction solution was quenched with water (150 mL), and the precipitated solid was collected by filtration, rinsed three times with water (20 mL), and dried in a forced air drying oven at 50°C for 8 hours to obtain intermediate I-1a as a yellow solid (2.23 g, yield 96.5%). LC-MS MS-ESI (m / z) 208.0 [M+H] + .

[0178] Preparation of intermediate: I-1e

[0179] Intermediate I-1c (2.23 g, 10.74 mmol, 1.0 eq) was dissolved in DMSO (30 mL), and Cs2CO3 (11.55 g, 35.44 mmol, 3.3 eq) and commercially available I-1d (2.02 g, 10.74 mmol, 1.0 eq) were added. The mixture was heated to 140°C with stirring for 3 hours and then cooled to room temperature. The reaction was quenched with water (150 mL), and the pH was adjusted to 6-7 with 1N dilute hydrochloric acid. The precipitated solid was collected by filtration, rinsed three times with water (20 mL), and dried in a forced air drying oven at 50°C for 8 hours to obtain intermediate I-1e as a brown solid (3.49 g, 90.4% yield). LC-MS MS-ESI (m / z) 360.1 [M+H] + .

[0180] Example 1: Preparation of Compound I-1

[0181] Intermediate I-1e (3.49 g, 9.71 mmol, 1.0 eq) was dissolved in ultra-dry DMF (40 mL). Commercially available 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 5.54 g, 14.56 mmol, 1.5 eq), N,N'-diisopropylethylamine (DIEA, 3.76 g, 29.13 mmol, 3.0 eq), and I-1f (1.05 g, 9.71 mmol, 1.0 eq) were added and stirred at room temperature for 18 hours. The reaction was quenched with water (200 mL), and the precipitated solid was collected by filtration, rinsed three times with water (20 mL), and dried in a forced air drying oven at 50°C for 8 hours. The crude product was separated on a silica gel column (200-300 mesh silica gel, eluted with ethyl acetate (EA) / petroleum ether (PE) = 0-1) and then slurried with EA / PE = 1:1 (30 mL) to obtain a yellow solid I-1 (2.30 g, yield 52.7%). LC-MS MS-ESI (m / z) 450.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 9.91(s,1H),8.64(d,J=5.2Hz,1H),8.44(d,J=9.2Hz,1H),8.25(d,J=9.1Hz,1H),8.09(d,J=8.2Hz, 1H),7.96-7.83(m,2H),7.67(t,J=7.6Hz,1H),7.58(dd,J=9.2,2.0Hz,1H),7.43(d,J=2.0Hz,1H),7 .38(d,J=7.6Hz,1H),7.32(dd,J=9.1,2.2Hz,1H),7.01(t,J=7.4Hz,1H),6.84(d,J=7.8Hz,1H),6.6 6(t,J=7.4Hz,1H),6.59(d,J=5.1Hz,1H),5.00(s,2H),4.23(q,J=6.9Hz,2H),1.44(t,J=6.9Hz,3H).

[0182] Example 2: Preparation of Compound I-2

[0183] Yellow solid I-2 was prepared from intermediate I-1e (200.00 mg, 0.56 mmol, 1.0 eq), HATU (319.28 mg, 0.84 mmol, 1.5 eq), DIEA (217.06 mg, 1.68 mmol, 3.0 eq), and I-2f (79.86 mg, 0.56 mmol, 1.0 eq) according to a similar procedure to Example I-1 (26.0 mg, 9.6% yield). LC-MS MS-ESI (m / z) 484.1 [M+H] + . 1 H-NMR (400 MHz, DMSO-d6) δ ppm 9.86(s,1H),8.63(d,J=5.1Hz,1H),8.42(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H) ,8.08(d,J=8.2Hz,1H),7.96-7.87(m,2H),7.66(t,J=7.6Hz,1H),7.62-7.50(m,1 H),7.46-7.36(m,2H),7.30(d,J=9.1Hz,1H),6.85(s,1H),6.65(d,J=8.3Hz,1H), 6.58(d,J=5.1Hz,1H),5.33(s,2H),4.23(q,J=6.9Hz,2H),1.43(t,J=6.9Hz,3H).

[0184] Preparation of intermediate: I-3c

[0185] Yellow solid intermediate I-3c was prepared from commercially available I-1a (1.79 g, 10.00 mmol, 1.0 eq), Cs2CO3 (4.15 g, 30.00 mmol, 3.0 eq), and I-3b (5.22 g, 30.00 mmol, 3.0 eq) following a similar procedure to that described for intermediate I-1c in Example 1 (1.86 g, 82.4% yield). LC-MS MS-ESI (m / z) 226.0 [M+H] + .

[0186] Preparation of intermediate: I-3e

[0187] Brown solid intermediate I-3e was prepared from intermediate I-3c (1.86 g, 8.24 mmol, 1.0 eq), Cs2CO3 (8.86 g, 27.19 mmol, 3.3 eq), and commercially available I-1d (1.55 g, 8.24 mmol, 1.0 eq) following a similar procedure to that described for intermediate I-1e in Example 1. (2.25 g, 72.3% yield). LC-MS MS-ESI (m / z) 378.1 [M+H] + .

[0188] Example 3: Preparation of Compound I-3

[0189] Yellow solid I-3 was prepared from intermediate I-3e (377.00 mg, 1.00 mmol, 1.0 eq), HATU (570.36 mg, 1.50 mmol, 1.5 eq), DIEA (387.82 mg, 3.00 mmol, 3.0 eq), and I-3f (162.12 mg, 1.00 mmol, 1.0 eq) according to a similar procedure to Example I-1 (130.0 mg, 24.9% yield). LC-MS MS-ESI (m / z) 522.1 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 10.04(s,1H),8.66(d,J=5.2Hz,1H),8.44(d,J=9.2Hz,1H),8.27(d,J=9.1Hz,1H),8 .11(d,J=8.3Hz,1H),7.95(d,J=7.0Hz,1H),7.92(d,J=2.2Hz,1H),7.67(t,J=7.7Hz ,1H),7.58(dd,J=9.2,2.4Hz,1H),7.51(dd,J=14.2,6.1Hz,2H),7.36(dd,J=9.1,2. 4Hz,1H),6.60(d,J=5.2Hz,1H),5.28(s,2H),4.98-4.74(m,2H),4.57-4.35(m,2H).

[0190] Example 4: Preparation of Compound I-4

[0191] Yellow solid I-4 was prepared from intermediate I-1e (200.00 mg, 0.56 mmol, 1.0 eq), HATU (319.28 mg, 0.84 mmol, 1.5 eq), DIEA (217.06 mg, 1.68 mmol, 3.0 eq), and I-4f (68.43 mg, 0.56 mmol, 1.0 eq) according to a similar procedure to Example I-1 (120.0 mg, 46.5% yield). LC-MS MS-ESI (m / z) 464.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.80(s,1H),8.63(d,J=4.8Hz,1H),8.42(d,J=9.0Hz,1H),8.24(d,J=9.1Hz,1H),8.07(d ,J=8.0Hz,1H),7.96-7.81(m,2H),7.65(t,J=7.4Hz,1H),7.57(d,J=8.5Hz,1H),7.42(s,1 H),7.30(d,J=8.4Hz,1H),7.23(d,J=7.9Hz,1H),6.63(s,1H),6.58(d,J=4.7Hz,1H),6.46 (d,J=7.5Hz,1H),4.92(s,2H),4.23(d,J=6.8Hz,2H),2.21(s,3H),1.43(t,J=6.7Hz,3H).

[0192] Example 5: Preparation of Compound I-5

[0193] Yellow solid I-5 was prepared from intermediate I-1e (200.00 mg, 0.56 mmol, 1.0 eq), HATU (319.28 mg, 0.84 mmol, 1.5 eq), DIEA (217.06 mg, 1.68 mmol, 3.0 eq), and I-5f (141.12 mg, 1.12 mmol, 2.0 eq) according to a similar procedure to Example I-1 (55.0 mg, 21.0% yield). LC-MS MS-ESI (m / z) 468.2 [M+H] + . 1 H-NMR (400 MHz, DMSO-d6) δ ppm 9.81(s,1H),8.64(d,J=5.2Hz,1H),8.44(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H ),8.08(d,J=8.3Hz,1H),7.94-7.88(m,2H),7.70-7.62(m,1H),7.57(dd,J=9.2, 2.5Hz,1H),7.43(d,J=2.4Hz,1H),7.38-7.26(m,2H),6.64-6.54(m,2H),6.42(t d,J=8.5,2.8Hz,1H),5.33(s,2H),4.24(q,J=6.9Hz,2H),1.44(t,J=7.0Hz,3H).

[0194] Example 6: Preparation of Compound I-6

[0195] Intermediate I-1e (1.08 g, 3.00 mmol, 1.0 eq) was dissolved in ultra-dry DMF (15 mL). HATU (1.71 g, 4.50 mmol, 1.5 eq), DIEA (1.16 g, 9.00 mmol, 3.0 eq), and I-6f (432.00 mg, 3.00 mmol, 1.0 eq) were added and stirred at room temperature for 18 h. The reaction was quenched with water (150 mL). The precipitated solid was collected by filtration, rinsed three times with water (5 mL), and dried in a forced air drying oven at 50°C for 8 h. The crude product was separated on a silica gel column (200-300 mesh silica gel, eluted with EA / PE = 0-1) and then slurried with EA / PE = 1:1 (30 mL) to obtain I-6 as a yellow solid (682.00 mg, 46.8% yield). LC-MS MS-ESI (m / z) 486.2 [M+H] + . 1H-NMR (400 MHz, DMSO-d6) δ ppm 9.93(s,1H),8.62(d,J=5.1Hz,1H),8.41(d,J=9.2Hz,1H),8.22(d,J=9.1Hz,1 H),8.07(d,J=8.1Hz,1H),7.93(d,J=6.9Hz,1H),7.88(s,1H),7.65(t,J=7.6H z,1H),7.55(d,J=8.9Hz,1H),7.40(s,1H),7.29(d,J=9.1Hz,1H),7.20(s,1H) ,6.70-6.52(m,2H),5.35(s,2H),4.21(q,J=6.8Hz,2H),1.41(t,J=6.9Hz,3H).

[0196] Preparation of intermediate: I-7c

[0197] Yellow solid intermediate I-7c was prepared from commercially available I-1a (230.00 mg, 1.28 mmol, 1.0 eq), Cs2CO3 (1.25 g, 3.84 mmol, 3.0 eq), and I-7b (652.80 mg, 3.84 mmol, 3.0 eq) according to a procedure similar to that described for intermediate I-1c in Example 1 (263.00 mg, 92.7% yield). LC-MS MS-ESI (m / z) 222.1 [M+H] + .

[0198] Preparation of intermediate: I-7e

[0199] Brown solid intermediate I-7e was prepared from homemade intermediate I-7c (263.00 mg, 1.19 mmol, 1.0 eq), Cs2CO3 (1.28 g, 3.93 mmol, 3.3 eq), and commercially available I-1d (223.96 mg, 1.19 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (392.00 mg, 88.2% yield). LC-MS MS-ESI (m / z) 374.2 [M+H] + .

[0200] Example 7: Preparation of Compound I-7

[0201] Yellow solid I-7 was prepared from intermediate I-7e (392.00 mg, 1.05 mmol, 1.0 eq), HATU (596.76 mg, 1.57 mmol, 1.5 eq), DIEA (406.98 mg, 3.15 mmol, 3.0 eq), and I-1f (113.55 mg, 1.05 mmol, 1.0 eq) according to a similar procedure to Example I-1 (174.0 mg, 35.7% yield). LC-MS MS-ESI (m / z) 464.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.89(s,1H),8.63(d,J=5.0Hz,1H),8.44(d,J=9.2Hz,1H),8.23(d,J=9.1Hz,1H),8.08(d,J=8.2Hz,1H),7.89(s,2H), 7.66(t,J=7.6Hz,1H),7.57(d,J=9.0Hz,1H),7.43(s,1H),7.38(d,J=7.6Hz,1H),7.28(d,J=9.0Hz,1H),7.00(t,J=7.3 Hz,1H),6.83(d,J=7.8Hz,1H),6.65(t,J=7.3Hz,1H),6.58(d,J=5.0Hz,1H),5.01(s,2H),4.87(dt,J=11.7,5.8Hz,1H),1.37(d,J=5.9Hz,6H).

[0202] Preparation of intermediate: I-8c

[0203] Yellow solid intermediate I-8c was prepared from commercially available I-1a (1.80 g, 10.02 mmol, 1.0 eq), Cs2CO3 (9.79 g, 30.06 mmol, 3.0 eq), and I-8b (4.27 g, 30.06 mmol, 3.0 eq) following a similar procedure to that described for intermediate I-1c in Example 1 (1.77 g, 91.2% yield). LC-MS MS-ESI (m / z) 194.0 [M+H] + .

[0204] Preparation of intermediate: I-8e

[0205] Brown solid intermediate I-8e was prepared from homemade I-8c (1.00 g, 5.16 mmol, 1.0 eq), Cs2CO3 (5.55 g, 17.03 mmol, 3.3 eq), and commercially available I-1d (971.11 mg, 5.16 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (1.41 g, yield 79.2%). LC-MS MS-ESI (m / z) 346.1 [M+H] + .

[0206] Example 8: Preparation of Compound I-8

[0207] Yellow solid I-8 was prepared from intermediate I-8e (104.0 mg, 0.30 mmol, 1.0 eq), HATU (171.10 mg, 0.45 mmol, 1.5 eq), DIEA (116.32 mg, 0.90 mmol, 3.0 eq), and I-8f (53.57 mg, 0.3 mmol, 1.0 eq) according to a procedure similar to Example I-1 (42.00 mg, 27.67% yield). LC-MS MS-ESI (m / z) 506.1 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ ppm 9.98(s,1H),8.63(d,J=5.2Hz,1H),8.41(d,J=9.2Hz,1H),8.23(d,J=9.1Hz,1H),8.08(d,J=8.3Hz,1H),7.94(d,J=6.9Hz,1H),7.88(d,J=2.4Hz ,1H),7.69-7.61(m,1H),7.58-7.49(m,2H),7.43(d,J=2.5Hz,1H),7.30 (dd,J=9.1,2.5Hz,1H),6.57(d,J=5.2Hz,1H),5.57(s,2H),3.93(s,3H).

[0208] Preparation of intermediate: I-9f-2

[0209] I-9f-1 (8.0 g, 0.46 mol, 1.0 eq) and 4-dimethylaminopyridine (DMAP, 0.281 g, 2.29 mmol, 0.05 eq) were dissolved in THF (500 mL) and cooled to 0°C in an ice bath. NaH (60% in mineral oil, 3.68 g, 0.092 mol, 2.0 eq) was added. After warming to room temperature, di-tert-butyl dicarbonate (Boc2O, 25.07 g, 0.115 mol, 2.5 eq) was added dropwise. The mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched with ice / water (300 mL) and extracted twice with ethyl acetate (300.0 mL). The organic phases were combined, washed once with saturated brine (300 mL), and concentrated. The crude product was separated on a silica gel column (200-300 mesh silica gel, eluted with EA / PE = 1:15) to obtain the product I-9f-2 as a light yellow solid. (15.2g, yield 88.4%). 1 H-NMR (400MHz, CDCl3) δppm 7.97-7.93 (m, 1H), 7.35-7.29 (m, 1H), 1.43 (s, 18H).

[0210] Preparation of intermediate: I-9f-3

[0211] I-9f-2 (15.20 g, 40.63 mmol, 1.0 eq) was dissolved in isopropanol (iPrOH, 170 mL) and Pd / C (2.0 g) was added. The resulting mixture was stirred at room temperature under a hydrogen atmosphere for 20 hours. Insoluble matter was removed by filtration through celite and rinsed three times with isopropanol (10 mL). The filtrate was concentrated to afford the product I-9f-3 as a yellow solid (13.44 g, 96.1% yield). LC-MS MS-ESI (m / z) 345.1 [M+H] + .

[0212] Preparation of intermediate: I-9f

[0213] I-9f-3 (13.44 g, 39.02 mmol, 1.0 eq) was dissolved in methanol (MeOH, 150 mL), and water (10 mL) and K2CO3 (15.00 g, 107.91 mmol, 2.77 eq) were added. The mixture was heated to 60°C with stirring for 24 hours and then cooled to room temperature. The reaction solution was concentrated, the residue was diluted with water (200 mL), and extracted three times with ethyl acetate (200 mL). The organic phases were combined, washed once with saturated brine (300 mL), and concentrated. The crude product was separated by silica gel column (200-300 mesh silica gel, eluted with EA / PE = 1 / 2) to obtain the product I-9f (9.41 g, yield 98.7%) as a light yellow solid. LC-MS MS-ESI (m / z) 189.1 [M-55] + . 1 H-NMR (400MHz, CDCl3) δppm 8.28 (brs, 1H), 7.02-6.95 (m, 1H), 6.46-6.43 (m, 1H), 4.93 (s, 2H), 1.43 (s, 9H).

[0214] Preparation of intermediate: I-9g

[0215] Intermediate I-8e (200.00 mg, 0.58 mmol, 1.0 eq) was dissolved in ultra-dry THF (10 mL). Commercially available N-methylimidazole (NMI, 214.28 mg, 2.61 mmol, 4.5 eq), I-9f (212.45 mg, 0.87 mmol, 1.5 eq), and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (TCFH, 243.60 mg, 0.87 mmol, 1.5 eq) were added and stirred at room temperature for 24 hours. The reaction mixture was concentrated, and the crude product was separated on a silica gel column (200-300 mesh silica gel, eluted with EA / PE = 0-1) to obtain intermediate I-9g as a yellow solid (157.0 mg, 47.3% yield). LC-MS MS-ESI (m / z) 572.2 [M+H] + .

[0216] Example 9: Preparation of Compound I-9

[0217] Intermediate I-9g (157.00 mg, 0.27 mmol, 1.0 eq) was dissolved in dichloromethane (DCM, 5 mL) and trifluoroacetic acid (TFA, 1.5 mL) was added. The mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated sodium bicarbonate solution (100 mL) and extracted twice with DCM. The organic phases were combined and concentrated. The crude product was separated on a silica gel column (200-300 mesh silica gel, eluted with EA / PE = 0-1) to obtain I-9 as a yellow solid (97.00 mg, yield 76.2%). LC-MS MS-ESI (m / z) 472.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.94(s,1H),8.63(d,J=5.2Hz,1H),8.41(d,J=9.2Hz,1H),8.23(d,J=9.1H z,1H),8.07(d,J=8.3Hz,1H),7.93(d,J=6.9Hz,1H),7.88(d,J=2.3Hz,1H), 7.72-7.60(m,1H),7.55(dd,J=9.2,2.4Hz,1H),7.43(d,J=2.4Hz,1H),7.30(dd,J =9.1,2.5Hz,1H),7.26-7.15(m,1H),6.74-6.51(m,2H),5.36(s,2H),3.94(s,3H).

[0218] Example 10: Preparation of Compound I-10

[0219] Yellow solid I-10 was prepared from intermediate I-8e (138.14 mg, 0.40 mmol, 1.0 eq), HATU (228.14 mg, 0.6 mmol, 1.5 eq), DIEA (155.0 mg, 1.2 mmol, 3.0 eq), and I-3f (97.27 mg, 0.60 mmol, 1.5 eq) according to a similar procedure to Example I-1 (45.60 mg, 23.29% yield). LC-MS MS-ESI (m / z) 490.1 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 10.01(s,1H),8.63(d,J=5.1Hz,1H),8.41(d,J=9.2Hz,1H),8.23(d,J=9.1Hz,1H),8.08(d,J=8.1Hz,1H),7.97-7.85(m,2H),7.65(t, J=7.5Hz,1H),7.59-7.46(m,2H),7.43(d,J=2.2Hz,1H),7.30(dd,J=9.1,2.2Hz,1H),6.58(d,J=5.1Hz,1H),5.24(s,2H),3.94(s,3H).

[0220] Intermediate: Preparation of I-11c

[0221] Yellow solid intermediate I-11c was prepared from commercially available I-1a (1.80 g, 10.00 mmol, 1.0 eq), Cs2CO3 (4.15 g, 30.00 mmol, 3.0 eq), and I-11b (3.66 g, 30.00 mmol, 3.0 eq) according to a procedure similar to that described for intermediate I-1c in Example 1 (1.65 g, yield 74.3%). LC-MS MS-ESI (m / z) 222.0 [M+H] + .

[0222] Preparation of intermediate: I-11e

[0223] Brown solid intermediate I-11e was prepared from homemade intermediate I-11c (1.65 g, 7.44 mmol, 1.0 eq), Cs2CO3 (8.00 g, 24.55 mmol, 3.3 eq), and commercially available I-1d (1.40 g, 7.44 mmol, 1.0 eq) following a similar procedure to that described for intermediate I-1e in Example 1. (2.30 g, 82.8% yield). LC-MS MS-ESI (m / z) 374.1 [M+H] + .

[0224] Example 11: Preparation of Compound I-11

[0225] Yellow solid I-11 was prepared from intermediate I-11e (1.30 g, 3.48 mmol, 1.0 eq), HATU (1.98 g, 5.22 mmol, 1.5 eq), DIEA (1.35 g, 10.44 mmol, 3.0 eq), and I-1f (376.19 mg, 3.48 mmol, 1.0 eq) according to a similar procedure to Example I-1. (590.00 mg, 36.6% yield). LC-MS MS-ESI (m / z) 464.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.88(s,1H),8.64(d,J=5.2Hz,1H),8.43(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H),8.08(d,J=8.2Hz,1H), 7.91-7.86(m,2H),7.66(t,J=7.7Hz,1H),7.57(dd,J=9.2,2.4Hz,1H),7.43(d,J=2.3Hz,1H),7.37(d,J= 7.7Hz,1H),7.31(dd,J=9.1,2.4Hz,1H),7.00(t,J=7.6Hz,1H),6.82(d,J=7.9Hz,1H),6.64(t,J=7.5Hz, 1H),6.59(d,J=5.2Hz,1H),5.00(s,2H),4.13(t,J=6.5Hz,2H),1.90-1.77(m,2H),1.05(t,J=7.4Hz,3H).

[0226] Example 12: Preparation of Compound I-12

[0227] Yellow solid I-12 was prepared from intermediate I-11e (200.00 mg, 0.54 mmol, 1.0 eq), HATU (307.96 mg, 0.81 mmol, 1.5 eq), DIEA (209.14 mg, 1.62 mmol, 3.0 eq), and I-5f (136.19 mg, 1.08 mmol, 2.0 eq) according to a similar procedure to Example I-1 (100.00 mg, 38.5% yield). LC-MS MS-ESI (m / z) 482.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 9.80(s,1H),8.64(d,J=5.2Hz,1H),8.44(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H),8.07(d,J=8.3Hz,1H),7.93-7.88( m,2H),7.71-7.60(m,1H),7.57(dd,J=9.2,2.5Hz,1H),7.43(d,J=2.4Hz,1H),7.37-7.26(m,2H),6.62-6.56(m,2H), 6.42(td,J=8.5,2.8Hz,1H),5.32(s,2H),4.13(t,J=6.5Hz,2H),1.90-1.76(m,2H),1.04(t,J=7.4Hz,3H).

[0228] Intermediate: Preparation of I-13c

[0229] Yellow solid intermediate I-13c was prepared from commercially available I-1a (1.80 g, 10.00 mmol, 1.0 eq), Cs2CO3 (4.15 g, 30.00 mmol, 3.0 eq), and I-13b (4.11 g, 30.00 mmol, 3.0 eq) according to a procedure similar to that described for intermediate I-1c in Example 1. (1.72 g, yield 73.0%). LC-MS MS-ESI (m / z) 236.1 [M+H] + .

[0230] Intermediate: Preparation of I-13e

[0231] Brown solid intermediate I-13e was prepared from homemade intermediate I-13c (705.00 mg, 3.00 mmol, 1.0 eq), Cs2CO3 (3.22 g, 9.90 mmol, 3.3 eq), and commercially available I-1d (564.60 mg, 3.00 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1 (850.00 mg, 73.1% yield). LC-MS MS-ESI (m / z) 388.2 [M+H] + .

[0232] Example 13: Preparation of Compound I-13

[0233] Yellow solid I-13 was prepared from intermediate I-13e (108.50 mg, 0.28 mmol, 1.0 eq), HATU (159.68 mg, 0.42 mmol, 1.5 eq), DIEA (108.53 mg, 0.84 mmol, 3.0 eq), and I-1f (30.27 mg, 0.28 mmol, 1.0 eq) according to a similar procedure to Example I-1 (37.00 mg, 27.7% yield). LC-MS MS-ESI (m / z) 478.3 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.88(s,1H),8.63(d,J=5.2Hz,1H),8.43(d,J=9.2Hz,1H),8.23(d,J=9.1Hz ,1H),8.08(d,J=8.3Hz,1H),7.91-7.86(m,2H),7.70-7.63(m,1H),7.57(dd, J=9.2,2.4Hz,1H),7.43(d,J=2.4Hz,1H),7.37(d,J=7.4Hz,1H),7.30(dd,J=9.1,2.4Hz,1H),7.00(t,J=7.1Hz,1H),6.82(d,J=7.5Hz,1H),6.64(t ,J=7.2Hz,1H),6.59(d,J=5.2Hz,1H),5.00(s,2H),4.17(t,J=6.4Hz,2H) ,1.88-1.73(m,2H),1.51(dq,J=14.7,7.4Hz,2H),0.97(t,J=7.4Hz,3H).

[0234] Example 14: Preparation of Compound I-14

[0235] Yellow solid I-14 was prepared from intermediate I-13e (1.40 g, 3.61 mmol, 1.0 eq), HATU (2.06 g, 5.41 mmol, 1.5 eq), DIEA (1.40 g, 10.83 mmol, 3.0 eq), and I-5f (455.22 mg, 3.61 mmol, 1.0 eq) according to a procedure similar to Example I-1 (1015.00 mg, 56.7% yield). LC-MS MS-ESI (m / z) 496.3 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 9.80(s,1H),8.63(d,J=5.2Hz,1H),8.43(d,J=9.2Hz,1H),8.23(d,J=9.1Hz,1H),8.07(d ,J=8.3Hz,1H),7.92-7.87(m,2H),7.69-7.62(m,1H),7.56(dd,J=9.2,2.5Hz,1H),7.43(d ,J=2.4Hz,1H),7.37-7.25(m,2H),6.67-6.51(m,2H),6.41(td,J=8.5,2.9Hz,1H),5.32(s ,2H),4.17(t,J=6.5Hz,2H),1.87-1.71(m,2H),1.61-1.44(m,2H),0.98(t,J=7.4Hz,3H).

[0236] Preparation of intermediate: I-15g

[0237] Intermediate I-15g, a yellow solid, was prepared from Intermediate I-1e (200.00 mg, 0.56 mmol, 1.0 eq), N-methylimidazole (206.89 mg, 2.52 mmol, 4.5 eq), I-15f (190.05 mg, 0.84 mmol, 1.5 eq), TCFH (235.70 mg, 0.84 mmol, 1.5 eq), and THF (10.0 mL) according to a similar procedure to Example I-9g (100.0 mg, 31.5% yield). LC-MS MS-ESI (m / z) 568.2 [M+H] + .

[0238] Example 15: Preparation of Compound I-15

[0239] Yellow solid I-15 was prepared from intermediate I-15g (100.0 mg, 0.18 mmol, 1.0 eq), TFA (1.5 mL), and DCM (5.0 mL) according to a similar procedure as in Example I-9 (60.00 mg, 71.3% yield). LC-MS MS-ESI (m / z) 468.2 [M+H] + . 1H-NMR (400 MHz, DMSO-d6) δ ppm 9.90(s,1H),8.61(d,J=5.2Hz,1H),8.41(d,J=9.2Hz,1H),8.21(d,J=9.1Hz,1H) ,8.07(d,J=8.2Hz,1H),7.92-7.82(m,2H),7.64(t,J=7.7Hz,1H),7.55(dd,J=9.2 ,2.4Hz,1H),7.42-7.35(m,2H),7.28(dd,J=9.1,2.4Hz,1H),6.88-6.76(m,2H), 6.56(d,J=5.2Hz,1H),4.91(s,2H),4.20(q,J=6.9Hz,2H),1.41(t,J=6.9Hz,3H).

[0240] Preparation of intermediate: I-16g

[0241] Intermediate I-16g, a yellow solid, was prepared from Intermediate I-1e (200.00 mg, 0.56 mmol, 1.0 eq), TCFH (235.70 mg, 0.84 mmol, 1.5 eq), NMI (206.89 mg, 2.52 mmol, 4.5 eq), and I-16f (190.05 mg, 0.84 mmol, 1.5 eq) according to a similar procedure to that described for Intermediate I-9g in Example 1 (100.00 mg, 31.5% yield). LC-MS MS-ESI (m / z) 568.2 [M+H] + .

[0242] Example 16: Preparation of Compound I-16

[0243] Yellow solid I-16 was prepared from intermediate I-16g (100.00 mg, 0.18 mmol, 1.0 eq) and TFA (1.5 mL) according to a similar procedure as in Example I-9 (60.00 mg, yield 71.3%). LC-MS MS-ESI (m / z) 468.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 10.04(s,1H),8.64 (d,J=5.2Hz,1H),8.42(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H),8.09(d,J=8.3Hz, 1H),7.94-7.88(m,2H),7.67(t,J=7.7Hz,1H),7.58(dd,J=9.2,2.4Hz,1H),7.43(d ,J=2.4Hz,1H),7.34-7.26(m,2H),7.07-6.91(m,1H),6.65(dd,J=14.0,8.0Hz,1H) ,6.59(d,J=5.2Hz,1H),4.99(s,2H),4.23(q,J=6.9Hz,2H),1.43(t,J=6.9Hz,3H).

[0244] Intermediate: Preparation of I-17a-3

[0245] Commercially available I-17a-2 (51.10 g, 354.60 mmol, 1.0 eq) was dissolved in trimethyl orthoformate (300.0 mL). The atmosphere was replaced with nitrogen three times, and the mixture was heated to 105°C. After stirring for 1 hour, I-17a-1 (50.00 g, 354.60 mmol) was added. Stirring was continued at this temperature for 1 hour, and the mixture was cooled to room temperature. n-Pentane (300 mL) was added, and the precipitated solid was collected by filtration, rinsed three times with n-pentane (30 mL), and dried in a forced air drying oven at 50°C for 8 hours to obtain the yellow solid intermediate I-17a-3 (86.00 g, 82.2% yield). LC-MS MS-ESI (m / z) 296.1 [M+H] + .

[0246] Intermediate: Preparation of I-17a-4

[0247] A mixture of I-17a-3 (60.00 g, 203.30 mmol, 1.0 eq) and diphenyl ether (500 mL) was heated to 220°C, stirred for 1 hour, and cooled to room temperature. Petroleum ether (500 mL) was added, and the precipitated solid was collected by filtration, rinsed three times with petroleum ether (50 mL), and dried. The crude product was separated by reverse-phase C18 column chromatography (acetonitrile / water / 0.1% TFA, 12-13%) to obtain I-17a-4 as a white solid (18.00 g, 46.0% yield). LC-MS MS-ESI (m / z) 194.0 [M+H] + .

[0248] Intermediate: Preparation of I-17a-5

[0249] A mixture of intermediate I-17a-4 (18.00 g, 93.30 mmol, 1.0 eq) and phosphorus oxychloride (50 mL) was heated to 110°C, stirred for 3 hours, and cooled to room temperature. The reaction solution was slowly added to ice / water to quench the mixture, and the pH was adjusted to 6-7 with 10% NaOH solution. The precipitated solid was collected by filtration, rinsed three times with water (10 mL), and dried. The crude product was separated on a silica gel column (200-300 mesh silica gel, eluted with EA / PE = 1:1) to obtain intermediate I-17a-5 as a yellow solid (16.10 g, yield 81.8%). LC-MS MS-ESI (m / z) 212.0 [M+H] + .

[0250] Intermediate: Preparation of I-17a

[0251] Intermediate I-17a-5 (12.00 g, 87.60 mmol, 1.0 eq) was dissolved in 1,2-dichloroethane (DCE, 100.0 mL), cooled to 0°C, and a 1.0 M solution of boron tribromide in dichloromethane (198.80 mL, 198.80 mmol, 2.27 eq) was added dropwise. After addition, the mixture was heated to 100°C, stirred for 8 hours, and cooled to room temperature. Methanol (100 mL) was slowly added to quench the reaction. Water (300 mL) was added, and the pH was adjusted to 12-13 with 10% NaOH solution. The organic and aqueous phases were separated, and the pH of the aqueous phase was adjusted to 5-6 with 2 M dilute hydrochloric acid. The precipitated solid was collected by filtration, rinsed three times with water (10.0 mL), and dried in a forced air drying oven at 50°C for 8 hours to obtain Intermediate I-17a as a yellow solid (9.10 g, 80.2% yield). LC-MS MS-ESI (m / z) 198.0 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δppm 10.82 (s, 1H), 8.67 (d, J = 4.8Hz, 1H), 7.48 (d, J = 4.8Hz, 1H), 7.19 (s, 1H), 7.08 (dd, J = 14.0, 2.3Hz, 1H).

[0252] Intermediate: Preparation of I-17c

[0253] Intermediate I-17c, a pale yellow solid, was prepared from Intermediate I-17a (800.00 mg, 4.05 mmol, 1.0 eq), Cs2CO3 (3.96 g, 12.15 mmol, 3.0 eq), and I-1b (1.32 g, 12.15 mmol, 3.0 eq) following a similar procedure to that described for Intermediate I-1c in Example 1 (810.00 mg, 88.7% yield). LC-MS MS-ESI (m / z) 226.0 [M+H] + .

[0254] Intermediate: Preparation of I-17e

[0255] Intermediate I-17e, a brown solid, was prepared from intermediate I-17c (450.00 mg, 2.00 mmol, 1.0 eq), Cs2CO3 (2.15 g, 6.60 mmol, 3.3 eq), and commercially available I-1d (376.40 mg, 2.00 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in the example. (640.00 mg, 84.8% yield). LC-MS MS-ESI (m / z) 378.2 [M+H] + .

[0256] Example 17: Preparation of Compound I-17

[0257] Yellow solid I-17 was prepared from intermediate I-17e (340.00 mg, 0.90 mmol, 1.0 eq), HATU (513.57 mg, 1.35 mmol, 1.5 eq), DIEA (348.69 mg, 2.70 mmol, 3.0 eq), and I-1f (97.31 mg, 0.90 mmol, 1.0 eq) according to a similar procedure to Example I-1 (99.00 mg, 23.5% yield). LC-MS MS-ESI (m / z) 467.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 9.86(s,1H),8.63(d,J=5.0Hz,1H),8.41(d,J=9.1Hz,1H),8.04(d,J=8.1Hz,1H),7.8 5(d,J=6.7Hz,1H),7.81(s,1H),7.63(t,J=7.5Hz,1H),7.54(d,J=8.6Hz,1H),7.35(d, J=7.5Hz,1H),7.29(s,1H),7.12(d,J=13.2Hz,1H),6.98(t,J=7.2Hz,1H),6.80(d,J= 7.7Hz,1H),6.71-6.52(m,2H),4.98(s,2H),4.33-4.12(m,2H),1.40(t,J=6.7Hz,3H).

[0258] Example 18: Preparation of Compound I-18

[0259] Yellow solid I-18 was prepared from intermediate I-17e (340.00 mg, 0.90 mmol, 1.0 eq), HATU (513.57 mg, 1.35 mmol, 1.5 eq), DIEA (348.69 mg, 2.70 mmol, 3.0 eq), and I-18f (113.53 mg, 0.90 mmol, 1.0 eq) according to a procedure similar to that of Example I-1. (282.00 mg, 64.5% yield). LC-MS MS-ESI (m / z) 486.2 [M+H] + . 1 H-NMR (400 MHz, DMSO-d6) δ ppm 10.03(s,1H),8.65(d,J=5.0Hz,1H),8.41(d,J=9.1Hz,1H),8.08(d,J=8.0Hz ,1H),7.90(d,J=6.6Hz,1H),7.83(s,1H),7.66(t,J=7.4Hz,1H),7.56(d,J=9 .0Hz,1H),7.38-7.23(m,2H),7.14(d,J=13.3Hz,1H),7.06-6.91(m,1H),6.6 5(d,J=4.9Hz,2H),4.99(s,2H),4.24(q,J=6.9Hz,2H),1.42(t,J=6.7Hz,3H).

[0260] Example 19: Preparation of Compound I-19

[0261] Yellow solid I-19 was prepared from intermediate I-17e (340.00 mg, 0.90 mmol, 1.0 eq), HATU (513.57 mg, 1.35 mmol, 1.5 eq), DIEA (348.69 mg, 2.70 mmol, 3.0 eq), and I-6f (129.60 mg, 0.90 mmol, 1.0 eq) according to a similar procedure to Example I-1 (164.00 mg, 36.2% yield). LC-MS MS-ESI (m / z) 504.2 [M+H] + . 1 H-NMR (400 MHz, DMSO-d6) δ ppm 9.95(s,1H),8.66(d,J=5.2Hz,1H),8.42(d,J=9.2Hz,1H),8.07(d,J=8.2Hz, 1H),7.94(d,J=7.0Hz,1H),7.83(s,1H),7.66(t,J=7.6Hz,1H),7.55(dd,J=9. 2,2.0Hz,1H),7.31(s,1H),7.28-7.18(m,1H),7.14(dd,J=13.4,1.9Hz,1H), 6.69-6.58(m,2H),5.37(s,2H),4.24(q,J=6.9Hz,2H),1.42(t,J=6.9Hz,3H).

[0262] Preparation of Intermediate: I-20g

[0263] Intermediate I-20g, a yellow solid, was prepared from Intermediate I-17e (340.00 mg, 0.90 mmol, 1.0 eq), TCFH (378.00 mg, 1.35 mmol, 1.5 eq), NMI (332.50 mg, 4.05 mmol, 4.5 eq), and I-15f (203.58 mg, 0.90 mmol, 1.0 eq) according to a procedure similar to that described in Example I-9g. (152.00 mg, 28.8% yield). LC-MS MS-ESI (m / z) 586.2 [M+H] + .

[0264] Example 20: Preparation of Compound I-20

[0265] Yellow solid I-20 was prepared from intermediate I-20g (152.0 mg, 0.26 mmol, 1.0 eq) and TFA (1.5 mL) according to a similar procedure as in Example I-9 (32.00 mg, 25.3% yield). LC-MS MS-ESI (m / z) 486.2 [M+H] + . 1 H-NMR (400 MHz, DMSO-d6) δ ppm 9.93(s,1H),8.66(d,J=5.2Hz,1H),8.42(d,J=9.2Hz,1H),8.07(d,J=8.2Hz,1 H),7.87(d,J=6.9Hz,1H),7.83(s,1H),7.66(t,J=7.7Hz,1H),7.60-7.51(m,1H ),7.40(d,J=8.1Hz,1H),7.31(s,1H),7.20-7.08(m,1H),6.92-6.75(m,2H),6. 66(d,J=5.2Hz,1H),4.93(s,2H),4.24(q,J=6.9Hz,2H),1.42(t,J=6.9Hz,3H).

[0266] Intermediate: Preparation of I-21b

[0267] Commercially available I-21b-1 (3.0 g, 24.01 mmol, 1.0 eq) was dissolved in DCM / H2O (30 mL / 30 mL), and KOAc (14.50 g, 148.00 mmol, 6.16 eq) was added. After cooling to 0°C in an ice / salt bath, I-21b-2 (15 mL, 96.45 mmol, 4.0 eq) was added dropwise. The ice / salt bath was removed, and the mixture was stirred at room temperature for 18 hours. The reaction solution was quenched with saturated NaHCO3 solution (100 mL) and extracted twice with DCM (50 mL). The organic phases were combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure below 5°C to afford intermediate I-21b as a yellow oil (1.10 g, 26.2% yield). LC-MS MS-ESI (m / z) 175.0 [M+H] + .

[0268] Intermediate: Preparation of I-21c

[0269] Yellow solid intermediate I-21c was prepared from commercially available I-1a (2.0 g, 11.13 mmol, 1.0 eq), Cs2CO3 (10.88 g, 33.39 mmol, 3.0 eq), and homemade intermediate I-21b (2.92 g, 16.69 mmol, 1.5 eq) following a similar procedure to that described for intermediate I-1c in Example 1 (2.46 g, 80.7% yield). LC-MS MS-ESI (m / z) 274.0 [M+H] + .

[0270] Intermediate: Preparation of I-21e

[0271] Brown solid intermediate I-21e was prepared from intermediate I-21c (2.46 g, 8.99 mmol, 1.0 eq), Cs2CO3 (9.67 g, 29.67 mmol, 3.3 eq), and commercially available I-1d (1.69 g, 8.99 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (3.42 g, yield 89.4%). LC-MS MS-ESI (m / z) 426.1 [M+H] + .

[0272] Example 21: Preparation of Compound I-21

[0273] Yellow solid I-21 was prepared from intermediate I-21e (1.27 g, 2.98 mmol, 1.0 eq), HATU (1.70 g, 4.47 mmol, 1.5 eq), DIEA (1.54 g, 11.92 mmol, 4.0 eq), and I-21f (427.93 mg, 2.98 mmol, 1.0 eq) according to a similar procedure to Example I-1. (514.00 mg, 33.4% yield). LC-MS MS-ESI (m / z) 515.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.05(d,J=6.5Hz,1H),8.62(d,J=5.2Hz,1H),8.35(d,J=9.2Hz,1H),8.23(d,J=9.1Hz,1H),8.03(d,J=8.1Hz,1H),7.85(d,J=2.4Hz,1 H),7.66(d,J=6.3Hz,1H),7.63-7.56(m,1H),7.53(dd,J=9.2,2.5Hz,1H),7.46(d,J=2.4Hz,1H),7.32(dd,J=9.1,2.4Hz,1H),6.78(t,2 J F-H =75.7Hz,1H),6.57(d,J=5.2Hz,1H),4.49-4.28(m,3H),4.28-4.18(m,2H),3.12-2.88(m,2H),2.85-2.66(m,2H).

[0274] Example 22: Preparation of Compound I-22

[0275] Yellow solid I-22 was prepared from intermediate I-21e (1.27 g, 2.98 mmol, 1.0 eq), HATU (1.70 g, 4.47 mmol, 1.5 eq), DIEA (1.15 g, 8.94 mmol, 3.0 eq), and I-6f (429.42 mg, 2.98 mmol, 1.0 eq) according to a similar procedure to Example I-1 (596.00 mg, 36.3% yield). LC-MS MS-ESI (m / z) 552.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.96(s,1H),8.66(d,J=5.2Hz,1H),8.43(d,J=9.2Hz,1H),8.27(d,J=9.2Hz,1H),8.09(d,J=8.3Hz,1H),7.96(d,J=7.0Hz,1H),7.91(d,J= 2.4Hz,1H),7.75-7.63(m,1H),7.58(dd,J=9.2,2.5Hz,1H),7.49(d,J=2.5Hz,1H),7.35(dd,J=9.2,2.5Hz,1H),7.30-7.16(m,1H),6.81(t, 2 J F-H =75.7Hz,1H),6.70-6.55(m,2H),5.38(s,2H),4.40(dd,J=5.4,2.9Hz,2H),4.27(dd,J=5.2,3.0Hz,2H).

[0276] Intermediate: Preparation of I-23c

[0277] Yellow solid intermediate I-23c was prepared from commercially available I-1a (2.0 g, 11.13 mmol, 1.0 eq), Cs2CO3 (10.88 g, 33.39 mmol, 3.0 eq), and commercially available I-23b (4.64 g, 33.39 mmol, 3.0 eq) according to a procedure similar to that described for intermediate I-1c in Example 1. (2.10 g, yield 79.4%). LC-MS MS-ESI (m / z) 238.1 [M+H] + .

[0278] Intermediate: Preparation of I-23e

[0279] Brown solid intermediate I-23e was prepared from intermediate I-23c (2.10 g, 8.83 mmol, 1.0 eq), Cs2CO3 (9.50 g, 29.14 mmol, 3.3 eq), and commercially available I-1d (1.66 g, 8.83 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (3.12 g, 90.7% yield). LC-MS MS-ESI (m / z) 390.1 [M+H] + .

[0280] Example 23: Preparation of Compound I-23

[0281] Yellow solid I-23 was prepared from intermediate I-23e (1.50 g, 3.85 mmol, 1.0 eq), HATU (2.19 g, 5.77 mmol, 1.5 eq), DIEA (1.99 g, 15.40 mmol, 4.0 eq), and I-21f (552.86 mg, 3.85 mmol, 1.0 eq) according to a procedure similar to Example I-1 (385.00 mg, 20.9% yield). LC-MS MS-ESI (m / z) 479.2 [M+H] + . 1H-NMR (400MHz, CDCl3) δppm8.62(d,J=5.2Hz,1H),8.47(d,J=9.2Hz,1H),8.29(d,J=9.2 Hz,1H),7.91(d,J=8.4Hz,1H),7.67-7.61(m,2H),7.53(t,J=7.7Hz,1H),7.48-7.41(m, 2H),7.33(d,J=9.2Hz,1H),6.51(d,J=5.2Hz,1H),6.31(d,J=6.8Hz,1H),4.62(s,1H),4 .37-4.29(m,2H),3.92-3.82(m,2H),3.52(s,3H),3.27-3.14(m,2H),2.73-2.60(m,2H).

[0282] Example 24: Preparation of Compound I-24

[0283] Yellow solid I-24 was prepared from intermediate I-23e (155.76 mg, 0.40 mmol, 1.0 eq), HATU (228.14 mg, 0.6 mmol, 1.5 eq), DIEA (155.00 mg, 1.2 mmol, 3.0 eq), and I-24f (59.85 mg, 0.40 mmol, 1.0 eq) according to a similar procedure to Example I-1 (85.00 mg, 43.8% yield). LC-MS MS-ESI (m / z) 485.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 8.82(d,J=7.3Hz,1H),8.64(d,J=5.2Hz,1H),8.33(d,J=9.2Hz,1H),8.25(d,J=9.1Hz,1H),8 .05-8.00(m,1H),7.87(d,J=2.4Hz,1H),7.63-7.59(m,2H),7.55(dd,J=9.2,2.5Hz,1H),7.47 (d,J=2.4Hz,1H),7.34(dd,J=9.1,2.4Hz,1H),6.58(d,J=5.2Hz,1H),4.67(s,2H),4.53(s,2 H),4.40-4.21(m,3H),3.79-3.74(m,2H),3.37(s,3H),2.71-2.59(m,2H),2.33-2.22(m,2H).

[0284] Example 25: Preparation of Compound I-25

[0285] Yellow solid I-25 was prepared from intermediate I-23e (155.76 mg, 0.40 mmol, 1.0 eq), HATU (228.14 mg, 0.6 mmol, 1.5 eq), DIEA (155.00 mg, 1.2 mmol, 3.0 eq), and I-25f (44.47 mg, 0.40 mmol, 1.0 eq) according to a similar procedure to Example I-1 (93.00 mg, 48.2% yield). LC-MS MS-ESI (m / z) 483.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 8.78(d,J=6.8Hz,1H),8.64(d,J=4.5Hz,1H),8.32(d,J=8.8Hz,1H),8.25(d,J=8 .9Hz,1H),8.02(s,1H),7.86(s,1H),7.66-7.50(m,3H),7.46(s,1H),7.33(d,J=8 .1Hz,1H),6.58(d,J=4.5Hz,1H),4.46-4.19(m,3H),3.84-3.72(m,2H),3.36(s, 3H),2.45-2.35(m,2H),2.13-2.00(m,4H),1.98-1.88(m,2H),1.87-1.76(m,2H).

[0286] Example 26: Preparation of Compound I-26

[0287] Yellow solid I-26 was prepared from intermediate I-23e (150.00 mg, 0.39 mmol, 1.0 eq), HATU (220.40 mg, 0.58 mmol, 1.5 eq), DIEA (201.24 mg, 1.56 mmol, 4.0 eq), and I-26f (38.69 mg, 0.39 mmol, 1.0 eq) according to a similar procedure to Example I-1 (40.00 mg, 21.8% yield). LC-MS MS-ESI (m / z) 471.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 8.64(d,J=5.1Hz,1H),8.49(d,J=7.9Hz,1H),8.32(d,J=9.2Hz,1H),8.25(d,J=9.1Hz,1H),8.01(d ,J=6.9Hz,1H),7.86(d,J=2.1Hz,1H),7.64-7.51(m,3H),7.47(d,J=2.0Hz,1H),7.34(dd,J=9.1,2 .1Hz,1H),6.58(d,J=5.1Hz,1H),4.39-4.25(m,2H),3.86(s,1H),3.82-3.72(m,2H),3.37(s,3H), 2.00-1.89(m,2H),1.85-173(m,2H),1.63(d,J=12.1Hz,1H),1.45-1.26(m,4H),1.23-1.09(s,1H).

[0288] Example 27: Preparation of Compound I-27

[0289] Yellow solid I-27 was prepared from intermediate I-23e (150.00 mg, 0.39 mmol, 1.0 eq), HATU (220.40 mg, 0.58 mmol, 1.5 eq), DIEA (201.24 mg, 1.56 mmol, 4.0 eq), and I-27f (34.75 mg, 0.39 mmol, 1.0 eq) according to a similar procedure to Example I-1 (40.00 mg, 22.3% yield). LC-MS MS-ESI (m / z) 461.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 8.96(d,J=6.9Hz,1H),8.64(d,J=5.2Hz,1H),8.34(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H),8 .03(d,J=7.9Hz,1H),7.87(d,J=2.3Hz,1H),7.69-7.58(m,2H),7.54(dd,J=9.2,2.4Hz,1H),7 .46(d,J=2.3Hz,1H),7.33(dd,J=9.1,2.4Hz,1H),6.58(d,J=5.2Hz,1H),5.41-5.15(m,1H), 4.64(d,J=3.7Hz,1H),4.36-4.25(m,2H),3.80-3.71(m,2H),3.35(s,3H),2.64-2.43(m,4H).

[0290] Intermediate: Preparation of I-28c

[0291] Intermediate I-28c, a pale yellow solid, was prepared from Intermediate I-17a (394.00 mg, 2.00 mmol, 1.0 eq), Cs2CO3 (1.96 g, 6.00 mmol, 3.0 eq), and homemade Intermediate I-21b (1.05 g, 6.00 mmol, 3.0 eq) following a similar procedure to that described for Intermediate I-1c in Example 1. (541.00 mg, 92.8% yield). LC-MS MS-ESI (m / z) 292.0 [M+H] + .

[0292] Intermediate: Preparation of I-28e

[0293] Brown solid intermediate I-28e was prepared from intermediate I-28c (541.00 mg, 1.86 mmol, 1.0 eq), Cs2CO3 (2.00 g, 6.14 mmol, 3.3 eq), and commercially available I-1d (349.68 mg, 1.86 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (702.00 mg, 85.1% yield). LC-MS MS-ESI (m / z) 444.1 [M+H] + .

[0294] Example 28: Preparation of Compound I-28

[0295] Yellow solid I-28 was prepared from intermediate I-28e (640.00 mg, 1.44 mmol, 1.0 eq), HATU (820.60 mg, 2.16 mmol, 1.5 eq), DIEA (557.28 mg, 4.32 mmol, 3.0 eq), and I-18f (181.58 mg, 1.44 mmol, 1.0 eq) according to a similar procedure to Example I-1 (259.00 mg, 32.6% yield). LC-MS MS-ESI (m / z) 552.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 10.04(s,1H),8.68(d,J=4.9Hz,1H),8.42(d,J=9.1Hz,1H),8.09(d,J=7.9Hz,1H),7.91(d,J=6.7Hz,1H),7.85(s,1H),7.67(t ,J=7.5Hz,1H),7.58(d,J=8.7Hz,1H),7.38(s,1H),7.30(d,J=7.7Hz,1H),7.21(d,J=13.0Hz,1H),7.02-6.94(m,1H),6.80(t, 2 J F-H =72.0Hz,1H),6.73-6.63(m,2H),5.00(s,2H),4.48-4.38(m,2H),4.31-4.22(m,2H).

[0296] Example 29: Preparation of Compound I-29

[0297] Yellow solid I-29 was prepared from intermediate I-28e (443.00 mg, 1.00 mmol, 1.0 eq), HATU (570.00 mg, 1.50 mmol, 1.5 eq), DIEA (516.00 mg, 4.0 mmol, 4.0 eq), and I-21f (143.56 mg, 1.0 mmol, 1.0 eq) according to a similar procedure to Example I-1 (182.00 mg, 34.2% yield). LC-MS MS-ESI (m / z) 533.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.06(d,J=6.4Hz,1H),8.66(d,J=5.1Hz,1H),8.36(d,J=9.2Hz,1H),8.03(d,J=7.9Hz,1H),7.81(s,1H),7. 67(d,J=6.8Hz,1H),7.64-7.57(m,1H),7.53(d,J=9.2Hz,1H),7.37(s,1H),7.20(d,J=13.2Hz,1H),6.79(t, 2 J F-H =75.7Hz,1H),6.65(d,J=5.1Hz,1H),4.52-4.31(m,3H),4.25(s,2H),3.15-2.95(m,2H),2.90-2.67(m,2H).

[0298] Example 30: Preparation of Compound I-30

[0299] Yellow solid I-30 was prepared from intermediate I-3e (1.60 g, 4.24 mmol, 1.0 eq), HATU (2.42 g, 6.36 mmol, 1.5 eq), DIEA (1.64 g, 12.72 mmol, 3.0 eq), and I-1f (458.34 mg, 4.24 mmol, 1.0 eq) according to a similar procedure to Example I-1. (1.20 g, yield 60.5%). LC-MS MS-ESI (m / z) 468.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.88(s,1H),8.65(d,J=5.2Hz,1H),8.45(d,J=9.2Hz,1H),8.27(d,J=9.1Hz,1H),8.08(d,J=8.3Hz ,1H),7.89(t,J=4.5Hz,2H),7.71-7.62(m,1H),7.58(dd,J=9.2,2.5Hz,1H),7.48(t,J=9.4Hz,1H), 7.42-7.29(m,2H),7.05-6.96(m,1H),6.85-6.80(m,1H),6.68-6.62(m,1H),6.61(d,J=5.2Hz,1H), 5.00(s,2H),4.94-4.87(m,1H),4.79(dd,J=4.5,2.9Hz,1H),4.52-4.46(m,1H),4.47-4.37(m,1H).

[0300] Example 31: Preparation of Compound I-31

[0301] Yellow solid I-31 was prepared from intermediate I-3e (250.00 mg, 0.66 mmol, 1.0 eq), HATU (376.20 mg, 0.99 mmol, 1.5 eq), DIEA (255.42 mg, 1.98 mmol, 3.0 eq), and I-18f (83.23 mg, 0.66 mmol, 1.0 eq) according to a similar procedure to Example I-1 (187.00 mg, 58.1% yield). LC-MS MS-ESI (m / z) 486.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 10.04(s,1H),8.66(d,J=5.2Hz,1H),8.43(d,J=9.2Hz,1H),8.27(d,J=9.1Hz,1H),8.10(d,J=8.3Hz ,1H),7.95-7.87(m,2H),7.73-7.62(m,1H),7.59(dd,J=9.2,2.5Hz,1H),7.49(d,J=2.5Hz,1H),7.3 6(dd,J=9.1,2.5Hz,1H),7.29(d,J=8.0Hz,1H),7.05-6.95(m,1H),6.70-6.63(m,1H),6.61(d,J=5. 2Hz,1H),4.99(s,2H),4.93-4.88(m,1H),4.83-4.75(m,1H),4.53-4.47(m,1H),4.45-4.37(m,1H).

[0302] Example 32: Preparation of Compound I-32

[0303] Yellow solid I-32 was prepared from intermediate I-3e (200.00 mg, 0.53 mmol, 1.0 eq), HATU (302.10 mg, 0.79 mmol, 1.5 eq), DIEA (205.11 mg, 1.59 mmol, 3.0 eq), and I-6f (76.37 mg, 0.53 mmol, 1.0 eq) according to a similar procedure to Example I-1 (80.00 mg, 30.0% yield). LC-MS MS-ESI (m / z) 504.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 9.93(s,1H),8.63(d,J=5.2Hz,1H),8.41(d,J=9.2Hz,1H),8.25(d,J=9.1Hz,1H),8.07(d,J=8 .3Hz,1H),7.93(d,J=7.0Hz,1H),7.89(d,J=2.3Hz,1H),7.69-7.62(m,1H),7.56(dd,J=9.2,2. 4Hz,1H),7.47(d,J=2.4Hz,1H),7.34(dd,J=9.1,2.5Hz,1H),7.26-7.15(m,1H),6.66-6.54(m, 2H),5.35(s,2H),4.92-4.83(m,1H),4.82-4.70(m,1H),4.54-4.45(m,1H),4.43-4.32(m,1H).

[0304] Example 33: Preparation of Compound I-33

[0305] Yellow solid I-33 was prepared from intermediate I-3e (150.95 mg, 0.4 mmol, 1.0 eq), HATU (228.14 mg, 0.6 mmol, 1.5 eq), DIEA (155.00 mg, 1.2 mmol, 3.0 eq), and I-21f (57.42 mg, 0.40 mmol, 1.0 eq) according to a similar procedure to Example I-1 (66.00 mg, 35.3% yield). LC-MS MS-ESI (m / z) 467.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.09(d,J=6.6Hz,1H),8.66(d,J=5.2Hz,1H),8.38(d,J=9.2Hz,1H),8.27(d,J=9.1Hz,1H ),8.06(d,J=8.2Hz,1H),7.89(d,J=2.5Hz,1H),7.71-7.67(m,1H),7.66-7.60(m,1H),7. 57(dd,J=9.2,2.5Hz,1H),7.50(d,J=2.4Hz,1H),7.37(dd,J=9.2,2.5Hz,1H),6.60(d,J= 5.2Hz,1H),4.97-4.74(m,2H),4.54-4.31(m,3H),3.13-2.94(m,2H),2.85-2.70(m,2H).

[0306] Example 34: Preparation of Compound I-34

[0307] Yellow solid I-34 was prepared from intermediate I-3e (150.95 mg, 0.4 mmol, 1.0 eq), HATU (228.14 mg, 0.60 mmol, 1.5 eq), DIEA (155.00 mg, 1.2 mmol, 3.0 eq), and I-34f (53.45 mg, 0.40 mmol, 1.0 eq) according to a similar procedure to Example I-1. (57.00 mg, 31.2% yield). LC-MS MS-ESI (m / z) 457.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δ ppm 8.96(d,J=7.2Hz,1H),8.66(d,J=5.1Hz,1H),8.35(d,J=9.2Hz,1H),8.28(d,J=9.1Hz,1H), 8.04(d,J=7.7Hz,1H),7.88(d,J=2.1Hz,1H),7.69-7.58(m,2H),7.56(dd,J=9.2,2.2Hz,1H ),7.50(d,J=2.0Hz,1H),7.37(dd,J=9.1,2.2Hz,1H),6.60(d,J=5.2Hz,1H),4.86(d,J=47. 8Hz,2H),4.75-4.65(m,1H),4.47(d,J=30.3Hz,2H),2.46-2.28(m,4H),0.57-0.40(m,4H).

[0308] Example 35: Preparation of Compound I-35

[0309] Yellow solid I-35 was prepared from intermediate I-3e (150.95 mg, 0.4 mmol, 1.0 eq), HATU (228.14 mg, 0.60 mmol, 1.5 eq), DIEA (155.00 mg, 1.2 mmol, 3.0 eq), and I-26f (39.68 mg, 0.40 mmol, 1.0 eq) according to a similar procedure to Example I-1 (40.00 mg, 21.8% yield). LC-MS MS-ESI (m / z) 459.2 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 8.64(d,J=5.1Hz,1H),8.49(d,J=7.9Hz,1H),8.29(dd,J=19.6,9.2Hz,2H),8.00(d,J=5.2 Hz,1H),7.86(d,J=1.7Hz,1H),7.63-7.51(m,3H),7.48(s,1H),7.35(dd,J=9.1,1.9Hz,1H) ,6.57(d,J=5.1Hz,1H),4.85(d,J=47.9Hz,2H),4.46(d,J=30.2Hz,2H),3.86(s,1H),1.96 -1.87(m,2H),1.81-1.70(m,2H),1.65-1.57(m,1H),1.42-1.26(m,4H),1.20-1.08(m,1H).

[0310] Intermediate: Preparation of I-36e

[0311] Brown solid intermediate I-36e was prepared from intermediate I-17a-5 (800.00 mg, 3.78 mmol, 1.0 eq), Cs2CO3 (4.07 g, 12.47 mmol, 3.3 eq), and commercially available I-1d (710.64 mg, 3.78 mmol, 1.0 eq) according to a similar procedure to that described for intermediate I-1e in Example 1. (1.00 g, yield 72.8%). LC-MS MS-ESI (m / z) 364.1 [M+H] + .

[0312] Example 36: Preparation of Compound I-36

[0313] Yellow solid I-36 was prepared from intermediate I-36e (200.00 mg, 0.55 mmol, 1.0 eq), HATU (313.50 mg, 0.82 mmol, 1.5 eq), DIEA (212.85 mg, 1.65 mmol, 3.0 eq), and commercially available I-36f (131.70 mg, 0.82 mmol, 1.5 eq) according to a similar procedure to Example I-1 (120.00 mg, 43.1% yield). LC-MS MS-ESI (m / z) 506.1 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 9.93(s,1H),8.66(d,J=4.7Hz,1H),8.44(d,J=9.0Hz,1H),8.07(d,J=7.9Hz,1H),7.96(d,J=6.6Hz,1H),7.83(s,1H),7.66(t, J=7.3Hz,1H),7.55(d,J=8.7Hz,1H),7.45-7.30(m,2H),7.16(d,J=13.2Hz,1H),6.72-6.60(m,2H),5.55(s,2H),3.96(s,3H).

[0314] Preparation of intermediate: I-37g

[0315] Intermediate I-37g, a yellow solid, was prepared from Intermediate I-36e (700.00 mg, 1.93 mmol, 1.0 eq), NMI (712.63 mg, 8.68 mmol, 4.5 eq), I-9f (705.74 mg, 2.89 mmol, 1.5 eq), TCFH (809.20 mg, 2.89 mmol, 1.5 eq), and THF (20.0 mL) according to a similar procedure to Example I-9g (462.00 mg, 40.6% yield). LC-MS MS-ESI (m / z) 590.2 [M+H] + .

[0316] Example 37: Preparation of Compound I-37

[0317] Yellow solid I-37 was prepared from intermediate I-37g (462.00 mg, 0.78 mmol, 1.0 eq), TFA (6 mL), and DCM (20 mL) according to a similar procedure as in Example I-9. (263.0 mg, yield 68.9%). LC-MS MS-ESI (m / z) 490.1 [M+H] + . 1H-NMR (400MHz, DMSO-d6) δppm 9.95 (s, 1H), 8.67 (d, J = 5.3Hz, 1H), 8.42 (d, J = 9.2Hz, 1H), 8.08 (d, J = 8.2Hz, 1H),7.94(d,J=6.8Hz,1H),7.84(d,J=2.4Hz,1H),7.76-7.60(m,1H),7.56(dd,J=9.2,2.5Hz,1H),7.34(d,J =2.2Hz,1H),7.27-7.19(m,1H),7.17(dd,J=13.4,2.4Hz,1H),6.77-6.51(m,2H),5.37(s,2H),3.96(s,3H).

[0318] Intermediate: Preparation of I-38c

[0319] Intermediate I-38c, a pale yellow solid, was prepared from Intermediate I-17a (396.00 mg, 2.00 mmol, 1.0 eq), Cs2CO3 (1.95 g, 6.00 mmol, 3.0 eq), and I-30b (1.04 g, 6.00 mmol, 3.0 eq) following a similar procedure to that described for Intermediate I-1c in Example 1. (460.00 mg, 94.4% yield). LC-MS MS-ESI (m / z) 244.0 [M+H] + .

[0320] Intermediate: Preparation of I-38e

[0321] Brown solid intermediate I-38e was prepared from intermediate I-38c (460.00 mg, 1.89 mmol, 1.0 eq), Cs2CO3 (2.03 g, 6.24 mmol, 3.3 eq), and commercially available I-1d (355.70 mg, 1.89 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (680.00 mg, 91.0% yield). LC-MS MS-ESI (m / z) 396.1 [M+H] + .

[0322] Example 38: Preparation of Compound I-38

[0323] Yellow solid I-38 was prepared from intermediate I-38e (680.00 mg, 1.72 mmol, 1.0 eq), HATU (980.40 mg, 2.58 mmol, 1.5 eq), DIEA (665.64 mg, 5.16 mmol, 3.0 eq), and commercially available I-6f (247.85 mg, 1.72 mmol, 1.0 eq) according to a similar procedure to Example I-1 (396.00 mg, 44.1% yield). LC-MS MS-ESI (m / z) 522.1 [M+H] + . 1 H-NMR(400 MHz,DMSO-d6)δppm 9.96(s,1H),8.67(d,J=5.2Hz,1H),8.42(d,J=9.2Hz,1H),8.08(d,J=8.3Hz,1H),7.94(d,J=7.0Hz,1H),7.84(d,J=2.3Hz,1H),7.71-7.62(m,1H ),7.56(dd,J=9.2,2.5Hz,1H),7.38(d,J=2.1Hz,1H),7.26-7.18(m,2H) ,6.71-6.57(m,2H),5.37(s,2H),4.94-4.71(m,2H),4.55-4.38(m,2H).

[0324] Intermediate: Preparation of I-39a-3

[0325] I-39a-1 (10.00 g, 70.85 mmol, 1.0 eq) was dissolved in isopropanol (200 mL), and I-39a-2 (15.80 g, 84.87 mmol, 1.2 eq) was added. The resulting mixture was heated to 70°C and stirred for 2 hours. After cooling to room temperature, n-pentane (200 mL) was added, and the precipitated solid was collected by filtration, rinsed three times with isopropanol / n-pentane (1:1, 10 mL), and dried in a forced air drying oven at 50°C for 8 hours to obtain the intermediate I-39a-3 as a white solid (17.0 g, 81.2% yield). LC-MS MS-ESI (m / z) 296.1 [M+H] + .

[0326] Intermediate: Preparation of I-39a-4

[0327] White solid intermediate I-39a-4 was prepared from intermediate I-39a-3 (12.00 g, 40.64 mmol, 1.0 eq) and diphenyl ether (300 mL) according to a similar procedure as in Example I-17a-4 (5.50 g, yield 70.0%). LC-MS MS-ESI (m / z) 194.0 [M+H] + .

[0328] Intermediate: Preparation of I-39a-5

[0329] White solid intermediate I-39a-5 was prepared from intermediate I-39a-4 (5.50 g, 28.47 mmol, 1.0 eq) and phosphorus oxychloride (30.0 mL) according to a similar procedure as in Example I-17a-5 (4.50 g, yield 74.7%). LC-MS MS-ESI (m / z) 212.0 [M+H] + .

[0330] Intermediate: Preparation of I-39a

[0331] Yellow solid intermediate I-39a was prepared from intermediate I-39a-5 (4.50 g, 21.27 mmol, 1.0 eq), 1.0 M boron tribromide in dichloromethane (75 mL, 75.00 mmol, 3.53 eq), and 1,2-dichloroethane (DCE, 210 mL) according to a procedure similar to that described in Example I-17a (2.10 g, 50.0% yield). LC-MS MS-ESI (m / z) 198.0 [M+H] + . 1 H-NMR (400MHz, DMSO-d6) δppm 11.22 (s, 1H), 8.68 (d, J = 4.0 Hz, 1H), 7.86 (d, J = 12.0 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H).

[0332] Intermediate: Preparation of I-39c

[0333] Intermediate I-39c, a pale yellow solid, was prepared from Intermediate I-39a (396.00 mg, 2.00 mmol, 1.0 eq), Cs2CO3 (1.95 g, 6.00 mmol, 3.0 eq), and I-30b (1.04 g, 6.00 mmol, 3.0 eq) following a similar procedure to that described for Intermediate I-1c in Example 1. (480.00 mg, 98.5% yield). LC-MS MS-ESI (m / z) 244.0 [M+H] + .

[0334] Intermediate: Preparation of I-39e

[0335] Brown solid intermediate I-39e was prepared from intermediate I-39c (480.00 mg, 1.97 mmol, 1.0 eq), Cs2CO3 (2.12 g, 6.50 mmol, 3.3 eq), and commercially available I-1d (370.75 mg, 1.97 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in the example. (710.00 mg, 91.1% yield). LC-MS MS-ESI (m / z) 396.1 [M+H] + .

[0336] Example 39: Preparation of Compound I-39

[0337] Yellow solid I-39 was prepared from intermediate I-39e (710.00 mg, 1.80 mmol, 1.0 eq), HATU (1.03 g, 2.70 mmol, 1.5 eq), DIEA (696.60 mg, 5.40 mmol, 3.0 eq), and commercially available I-6f (259.38 mg, 1.80 mmol, 1.0 eq) according to a similar procedure to Example I-1. (54.00 mg, 5.8% yield). LC-MS MS-ESI (m / z) 522.1 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.96(s,1H),8.65(d,J=5.1Hz,1H),8.44(d,J=9.2Hz,1H),8.09(t,J=10.8Hz,2H),8.02-7.87(m,2H),7.79-7.62(m,2H), 7.58(d,J=8.8Hz,1H),7.29-7.17(m,1H),6.76-6.53(m,2H),5.37(s,2H),4.88(d,J=47.8Hz,2H),4.56(d,J=29.7Hz,2H).

[0338] Intermediate: Preparation of I-40c

[0339] Intermediate I-40c, a pale yellow solid, was prepared from I-1a (1.79 g, 10.0 mmol, 1.0 eq), Cs2CO3 (9.77 g, 30.0 mmol, 3.0 eq), and I-40b (4.30 g, 30.0 mmol, 3.0 eq) following a similar procedure to that described for intermediate I-1c in Example 1. (2.25 g, 92.9% yield). LC-MS MS-ESI (m / z) 242.0 [M+H] + .

[0340] Intermediate: Preparation of I-40e

[0341] Brown solid intermediate I-40e was prepared from intermediate I-40c (2.25 g, 9.29 mmol, 1.0 eq), Cs2CO3 (9.98 g, 30.65 mmol, 3.3 eq), and commercially available I-1d (1.75 g, 9.29 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (3.20 g, yield 87.46%). LC-MS MS-ESI (m / z) 394.1 [M+H] + .

[0342] Example 40: Preparation of Compound I-40

[0343] Yellow solid I-40 was prepared from intermediate I-40e (157.53 mg, 0.40 mmol, 1.0 eq), HATU (228.14 mg, 0.6 mmol, 1.5 eq), DIEA (155.00 mg, 1.2 mmol, 3.0 eq), and I-40f (28.45 mg, 0.40 mmol, 1.0 eq) according to a similar procedure to Example I-1 (42.00 mg, 23.5% yield). LC-MS MS-ESI (m / z) 447.1 [M+H] + . 1H-NMR(400MHz,DMSO-d6)δppm 8.86(d,J=7.6Hz,1H),8.66(d,J=5.1Hz,1H),8.34(d,J=9.2Hz,1H),8.28(d,J=9.1Hz,1H ),8.03(d,J=7.0Hz,1H),7.88(d,J=2.3Hz,1H),7.64-7.58(m,2H),7.55(dd,J=9.2,2.4H z,1H),7.49(d,J=2.2Hz,1H),7.37(dd,J=9.1,2.3Hz,1H),6.60(d,J=5.2Hz,1H),4.55-4 .45(m,3H),4.12-4.03(mm,2H),2.35-2.25(m,2H),2.15-2.02(m,2H),1.76-1.67(m,2H).

[0344] Intermediate: Preparation of I-41c

[0345] Yellow solid intermediate I-41c was prepared from commercially available I-1a (1.80 g, 10.02 mmol, 1.0 eq), Cs2CO3 (9.79 g, 30.06 mmol, 3.0 eq), and I-41b (4.36 g, 30.06 mmol, 3.0 eq) according to a procedure similar to that described for intermediate I-1c in Example 1 (1.70 g, yield 69.6%). LC-MS MS-ESI (m / z) 244.0 [M+H] + .

[0346] Intermediate: Preparation of I-41e

[0347] Brown solid intermediate I-41e was prepared from homemade intermediate I-41c (731.00 mg, 3.00 mmol, 1.0 eq), Cs2CO3 (3.22 g, 9.90 mmol, 3.3 eq), and commercially available I-1d (564.60 mg, 3.00 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1. (800.00 mg, 67.4% yield). LC-MS MS-ESI (m / z) 396.1 [M+H] + .

[0348] Example 41: Preparation of Compound I-41

[0349] Yellow solid I-41 was prepared from intermediate I-41e (110.70 mg, 0.28 mmol, 1.0 eq), HATU (159.68 mg, 0.42 mmol, 1.5 eq), DIEA (108.53 mg, 0.84 mmol, 3.0 eq), and I-41f (40.20 mg, 0.28 mmol, 1.0 eq) according to a similar procedure to Example I-1 (40.00 mg, 29.5% yield). LC-MS MS-ESI (m / z) 485.1 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.09(d,J=6.5Hz,1H),8.68(d,J=5.1Hz,1H),8.39(d,J=9.2Hz,1H),8.29(d,J=9.2Hz,1H), 8.06(d,J=8.1Hz,1H),7.89(d,J=2.2Hz,1H),7.70(d,J=6.7Hz,1H),7.67-7.60(m,1H),7.59 -7.53(m,2H),7.40(dd,J=9.2,2.3Hz,1H),6.62(d,J=5.2Hz,1H),6.52(tt,J=56.0,3.2Hz, 1H),4.57(td,J=14.7,3.2Hz,2H),4.45-4.30(m,1H),3.13-2.96(m,2H),2.88-2.70(m,2H).

[0350] Intermediate: Preparation of I-42c

[0351] Yellow solid intermediate I-42c was prepared from commercially available I-1a (1.80 g, 10.02 mmol, 1.0 eq), Cs2CO3 (9.79 g, 30.06 mmol, 3.0 eq), and I-42b (2.33 g, 10.02 mmol, 1.0 eq) following a similar procedure to that described for intermediate I-1c in Example 1 (1.60 g, yield 63.7%). LC-MS MS-ESI (m / z) 251.1 [M+H] + .

[0352] Preparation of intermediate: I-42e

[0353] Brown solid intermediate I-42e was prepared from homemade intermediate I-42c (752.10 mg, 3.00 mmol, 1.0 eq), Cs2CO3 (3.22 g, 9.90 mmol, 3.3 eq), and commercially available I-1d (564.60 mg, 3.00 mmol, 1.0 eq) following a similar procedure to that described for intermediate I-1e in Example 1 (800.00 mg, 66.2% yield). LC-MS MS-ESI (m / z) 403.2 [M+H] + .

[0354] Example 42: Preparation of Compound I-42

[0355] Yellow solid I-42 was prepared from intermediate I-42e (112.67 mg, 0.28 mmol, 1.0 eq), HATU (159.68 mg, 0.42 mmol, 1.5 eq), DIEA (108.53 mg, 0.84 mmol, 3.0 eq), and I-21f (40.21 mg, 0.28 mmol, 1.0 eq) according to a similar procedure to Example I-1 (40.00 mg, 29.1% yield). LC-MS MS-ESI (m / z) 492.2 [M+H] + .

[0356] Intermediate: Preparation of I-43c

[0357] Yellow solid intermediate I-43c was prepared from commercially available I-1a (1.80 g, 10.02 mmol, 1.0 eq), Cs2CO3 (9.79 g, 30.06 mmol, 3.0 eq), and I-43b (1.78 g, 10.02 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1c in Example 1. (1.60 g, 57.7% yield). LC-MS MS-ESI (m / z) 277.1 [M+H] + .

[0358] Intermediate: Preparation of I-43e

[0359] Brown solid intermediate I-43e was prepared from homemade intermediate I-43c (830.40 mg, 3.00 mmol, 1.0 eq), Cs2CO3 (3.22 g, 9.90 mmol, 3.3 eq), and commercially available I-1d (564.60 mg, 3.00 mmol, 1.0 eq) according to a procedure similar to that described for intermediate I-1e in Example 1 (850.00 mg, 66.1% yield). LC-MS MS-ESI (m / z) 429.2 [M+H] + .

[0360] Example 43: Preparation of Compound I-43

[0361] Yellow solid I-43 was prepared from intermediate I-43e (119.98 mg, 0.28 mmol, 1.0 eq), HATU (159.68 mg, 0.42 mmol, 1.5 eq), DIEA (108.53 mg, 0.84 mmol, 3.0 eq), and I-6f (40.32 mg, 0.28 mmol, 1.0 eq) according to a similar procedure to Example I-1 (40.00 mg, 25.7% yield). LC-MS MS-ESI (m / z) 555.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 9.96(s,1H),8.64(d,J=5.2Hz,1H),8.43(d,J=9.2Hz,1H),8.24(d,J=9.1Hz,1H),8.09(d,J=8.3 Hz,1H),7.95(d,J=6.6Hz,1H),7.90(d,J=2.4Hz,1H),7.71-7.63(m,1H),7.57(dd,J=9.2,2.5Hz, 1H),7.46(d,J=2.5Hz,1H),7.32(dd,J=9.1,2.5Hz,1H),7.27-7.19(m,1H),6.72-6.56(m,2H),5 .38(s,2H),4.27(t,J=5.8Hz,2H),2.89(t,J=5.7Hz,2H),2.65-2.52(m,4H),1.83-1.58(mm,4H).

[0362] Example 44: Preparation of Compound I-44

[0363] Yellow solid I-44 was prepared from intermediate I-1e (205.0 mg, 0.57 mmol, 1.0 eq), HATU (325.10 mg, 0.855 mmol, 1.5 eq), DIEA (221.00 mg, 1.71 mmol, 3.0 eq), and I-3f (92.41 mg, 0.57 mmol, 1.0 eq) according to a similar procedure to Example I-1 (65.00 mg, 22.65% yield). LC-MS MS-ESI (m / z) 504.2 [M+H] + . 1 H-NMR(400MHz,DMSO-d6)δppm 10.03(s,1H),8.64(d,J=4.9Hz,1H),8.43(d,J=9.1Hz,1H),8.24(d,J=9.1Hz,1H),8.10(d,J=8.1Hz,1H),7.98-7.87(m,2H),7.67(t,J=7.6Hz ,1H),7.60-7.46(m,2H),7.42(s,1H),7.30(d,J=9.0Hz,1H),6.58(d,J=4.9Hz,1H),5.27(s,2H),4.23(d,J=6.9Hz,2H),1.43(t,J=6.7Hz,3H).

[0364] In addition, other compounds of the present invention can be prepared according to similar steps to those in the above examples.

[0365] In vitro biological evaluation

[0366] Example A: Inhibitory activity and relative selectivity of the compounds of the present invention against Aurora B and VEGFR2 kinases

[0367] Prepare compound gradient concentration DMSO working solutions: prepare the compound into 0.2 mM DMSO solution, and dilute it into 10 gradient concentration working solutions with DMSO (corresponding to the final concentrations of the compound in the reaction system of 1000 nM, 300 nM, 100 nM, 30 nM, 10 nM, 3 nM, 1 nM, 0.3 nM, 0.1 nM, and 0.03 nM).

[0368] Aurora B kinase and VEGFR2 inhibitory activity test: The half-maximal inhibitory concentration (IC50) of the compound on Aurora B kinase and VEGFR2 was tested by HTRF KinEASE-TK kit (Cisbio, Cat#62TK0PEC) and HTRF KinEASE-STK kit (Cisbio, Cat#61ST2BLE), respectively. 50Prepare 2× Kinase & Metal solution (Aurora B / Cat#05-102 and VEGFR2 / Cat#08-191, both purchased from Carna) and 2× Substrate & ATP solution (using substrates S2 and TK for Aurora B and VEGFR2, respectively) according to the kit instructions. Add 25 nL of the working solution of the test compound at each gradient concentration and 2.5 μL of 2× Kinase & Metal solution to each well of a 384-well plate. Seal the plate with film, mix thoroughly, centrifuge, and incubate at 25°C for 10 minutes. Then, add 2.5 μL of 2× Substrate & ATP solution to each well and incubate again at 25°C for 30 minutes. Finally, add 5 μL of 2× XL665 & Antibody kinase assay reaction solution to each well. After incubation at 25°C for 60 minutes, read the fluorescence signal of each well at 665 nm and 620 nm using a microplate reader.

[0369] The fluorescence signal ratio of 665 nm / 620 nm of each well was calculated (X), and the well without compound was used as the negative reference (Y) and the well without enzyme was used as the positive reference (Z). The inhibition rate of the compound on the corresponding kinase in each test well was calculated by the formula: Inhibition (%) = 100% - (XZ) / (YZ) × 100%, and the half-maximal inhibitory concentration (IC) of each compound on the corresponding kinase was calculated using GraphPad 7.0 software. 50 ).

[0370] The relative selectivity of the inhibitory potency of Aurora B kinase was evaluated by the IC value of the compound against VEGFR2. 50 With IC of Aurora B 50 The ratio of IC 50-VEGFR2 / IC 50-Aurora B The larger the ratio, the stronger the compound's inhibitory effect on Aurora B compared to VEGFR2. The specific data are shown in Table 2 below:

[0371] Table 2 Inhibitory activity and relative selectivity of the compounds of the present invention against Aurora B and VEGFR2 kinases

[0372] Compounds 31 (Chiauranib) and 32 are examples disclosed in patent CN101906076A. The inventors synthesized these two compounds based on the synthesis method described therein for use as reference molecules. The structural formulas of these two compounds are as follows:

[0373] The results in Table 2 demonstrate that the compounds of the present invention possess excellent Aurora B kinase inhibitory activity and very high Aurora B kinase selectivity over VEGFR2. Specifically, compared to control molecule 01 (Chiauranib), control molecule 02, and control examples I-7, I-11, I-12, I-13, and I-14, the compounds of the present invention not only exhibit stronger inhibitory activity against Aurora B kinase, with an IC50 of less than 10 nM, but also exhibit very high Aurora B kinase selectivity over VEGFR2, with an IC50-VEGFR2 / IC50-Aurora B ratio exceeding 7, achieving unexpected technical benefits.

[0374] Example B Testing of the Effects of the Compounds of the Invention on Tumor Cell Cycle

[0375] When Aurora B kinase activity is inhibited in tumor cells, cytokinesis fails due to disruption of chromosome alignment and segregation, resulting in tetraploidy or polyploidy. This leads to severe genomic instability and mitotic catastrophe, leading to cell apoptosis. The fluorescent dye propidium iodide (PI), which specifically binds to nucleic acids, can be used to calibrate the DNA content within cells, allowing for the classification of cell states into sub-G0 / G1 (apoptosis), G0 / G1, S, G2 / M (tetraploidy), and polyploidy. Sub-G0 / G1 refers to a DNA content of less than 2N, generally considered to be in the process of apoptosis (random DNA degradation and cell membrane permeability); polyploidy refers to a DNA content of more than 4N.

[0376] Experimental process:

[0377] Human acute lymphoblastic leukemia cells Molt-4 (CRL-1582) were purchased from American Type Culture Collection (ATCC). Molt-4 cells in suspension culture and logarithmic growth phase were collected and counted. 6 Cells were seeded into six-well plates and cultured overnight. The test compound was prepared into 1mM and 3mM DMSO solutions, and the DMSO solution was diluted 50 times with culture medium. Finally, the above solution was added to the culture system at a volume ratio of 1:19, so that the final concentration of the compound in each well reached 1μM or 3μM, respectively. After further culture for 48 hours, the cells were collected by centrifugation. Each cell sample was resuspended in 300μl PBS and added dropwise to 700μl pre-cooled anhydrous ethanol, and then gently inverted several times to mix. At this point, the cells were collected and fixed. The samples were left to stand at 4°C for more than 12 hours before flow cytometric analysis.

[0378] Mix PBS with 10 mg / mL PI stock solution and 10 mg / mL RNase A solution at a ratio of 1000:5:2 to create the working staining solution. Centrifuge the fixed cell sample at 1000 rpm for 10 minutes at 4°C. Aspirate the supernatant and wash twice with PBS. Resuspend 300 μL per tube in the working staining solution. Incubate at 37°C in the dark for 30 minutes. Filter the cells through a 200-mesh stainless steel mesh, and perform flow cytometry analysis on the filtrate (count 10,000 cells per sample).

[0379] Histograms showing DNA content were obtained by flow cytometry. The cycle distribution in each sample was analyzed using FlowJo flow cytometry data analysis software. The mean (X) and standard deviation (SD) were calculated. Data are presented as X ± SD. The apoptosis, tetraploidy, and polyploidy ratios of Molt-4 cells after treatment with different doses of the test compounds are shown in Table 3 below.

[0380] Table 3 Test results of the effects of the compounds of the present invention on the Molt-4 cell cycle

[0381] The results in Table 3 show that, whether at a dose of 1 μM or 3 μM, the compounds of the present invention have significantly improved effects on inducing tetraploidy, polyploidy and apoptosis in Molt-4 cells compared with control molecules 01 (Chiauranib) and 02, indicating that the compounds of the present invention have a stronger inhibitory effect on Aurora B kinase activity in tumor cells, thereby affecting the cell cycle of tumor cells, and can achieve better efficacy / safety comprehensive benefits for related diseases.

[0382] Example C Brain Penetration Test of the Compounds of the Invention

[0383] To test the ability of the compounds of this invention to cross the blood-brain barrier (BBB), 6-week-old B / C female mice (purchased from the Guangdong Medical Animal Experimental Center) were gavage-administered with the compounds of this invention at a dose of 5 mg / kg in a vehicle containing 5% dimethyl sulfoxide, 60% 1,3-propylene glycol, and 35% purified water. Four hours after administration, the animals were sacrificed, and blood and brain tissue were collected. Blood was anticoagulated with K2-EDTA and centrifuged at 5000 rpm for 5 minutes to separate plasma. Brain tissue was accurately weighed and homogenized with a predetermined amount of phosphate-buffered saline (PBS). The biological samples were frozen at -80°C until analysis. After sample extraction, compound concentrations were determined using liquid chromatography-mass spectrometry (LC-MS / MS). Brain penetration was defined as the ratio of compound concentration in brain tissue to that in plasma.

[0384] Table 4 Brain penetration experimental data

[0385] The results in Table 4 show that in brain penetration testing, the ratio of the compound concentration in brain tissue to the plasma concentration of the compound of the present invention was significantly higher than that of the control molecules 01 (Chiauranib) and 02. These test results demonstrate that the compound of the present invention has excellent brain barrier permeability, can cross the blood-brain barrier, has the potential to achieve effective blood concentrations in brain tissue, and can be used to treat and prevent central nervous system-related diseases.

[0386] Example D Antitumor efficacy of the compounds of the present invention in the PANC02 mouse pancreatic cancer model

[0387] A mouse PANC02 pancreatic cancer xenograft model was established using C57BL / 6 female mice (6 weeks old). The tumor cells were PANC02 (mouse pancreatic cancer cells). The cell culture medium was DMEM supplemented with 1% double-antibody and 10% fetal bovine serum. PANC02 cells in the logarithmic growth phase and growing well were collected and plated at 0.9×10 6 The tumor was inoculated subcutaneously on the left side of C57BL / 6 mice at a concentration of 0.2 mL. The long diameter (a, mm) and short diameter (b, mm) of the tumor and the tumor volume (V, mm) were measured with a vernier caliper. 3 ) The calculation formula is V = 1 / 2a*b 2 Tumor volume was measured 2-3 times a week using a vernier caliper. The average tumor volume in mice reached 190 mm 3 At 4 h and above, the animals were divided into groups and dosed, with 8 mice per group. The grouping day was designated as Day 0 (i.e., Day 0). The animals were divided into 4 groups: the solvent control group (0.2% CMC-Na aqueous solution), the compound I-9 group (10 mg / kg / day), the control molecule 01 group (Chiauranib) (10 mg / kg / day), and the control molecule 02 group (10 mg / kg / day). All 4 groups were administered by gavage once daily for a continuous period of time, with the experiment ending on the day of the last dose.

[0388] Tumor volume results are expressed as mean ± SEM. Comparisons between the two groups will be detected using the Mann Whitney test. If p < 0.05, it is considered to be statistically significant. The calculation formula for tumor volume inhibition rate (TGI) is TGI (%) = [1-(Ti-T0) / (Vi-V0)] × 100%. (Ti: mean tumor volume of the treatment group on the i-th day of administration, T0: mean tumor volume of the treatment group on the 0th day of administration; Vi: mean tumor volume of the solvent control group on the i-th day of administration, V0: mean tumor volume of the solvent control group on the 0th day of administration)

[0389] The average tumor volume and tumor volume inhibition rate of each group of mice on different dosing days are shown in Table 5, and the statistical results of the average tumor volume are shown in Figure 1.

[0390] Table 5: Average tumor volume and tumor volume inhibition rate

[0391] As shown in Figure 1, on day 9 of group administration, the tumor volume of mice in the Compound I-9 group was significantly reduced compared to the control molecule 01 (Chiauranib) group (p < 0.01). Compared to the control molecule 02 group, the tumor volume of mice in the Compound I-9 group was significantly reduced (p < 0.05). Compared to the solvent control group, the tumor volume of mice in the Compound I-9 group was significantly reduced (p < 0.001).

[0392] As shown in Table 5, the tumor volume inhibition rate of the representative compound I-9 group (TGI is 114.0%) is significantly better than that of the control molecule 01 (Chiauranib) group (TGI is 74.6%) and the control molecule 02 group (TGI is 68.9%).

[0393] In summary, the compounds of the present invention have excellent anti-tumor efficacy in vivo and can significantly inhibit tumor growth.

[0394] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A compound represented by formula (I), or a stereoisomer, tautomer, polymorph, cocrystal, solvate, metabolite, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof: in: R 1 is selected from methyl or ethyl, the methyl or ethyl being unsubstituted or substituted by one or more identical or different R a replace; Each R a are each independently selected from halogen, C 1-6 Alkoxy, -NR'R", halogenated C 1-6 Alkoxy; wherein R' and R" are each independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, or R' and R" together with the N atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, S; R 2 and R 3 Each independently selected from: H, halogen, C 1-6 alkyl; Ring A is selected from C 4-10 Cycloalkyl or 4-10 membered heterocyclic group; the 4-10 membered heterocyclic group contains 1 to 4 heteroatoms selected from N, O, S; the C 4-10 The cycloalkyl or 4-10 membered heterocyclic group is unsubstituted or substituted by one or more identical or different R b replace; Each R b are each independently selected from halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl; Alternatively, ring A is selected from the group in, In A1, R 4 Selected from F, Cl, C 1-6 Alkyl, haloC 1-6 alkyl; In A2, R 5 Selected from halogen, C 1-6 Alkyl, haloC 1-6 alkyl; In A3, R 4 and R 5 are each independently selected from halogen, C 1-6 Alkyl, haloC 1-6 alkyl; A4, R 6 Selected from F or Cl, R 4 and R 5 are each independently selected from halogen, C 1-6 Alkyl, haloC 1-6 Alkyl, when R 6 When it is Cl, R 1 is methyl or ethyl; A5, R 5 and R 6 are each independently selected from halogen, C 1-6 Alkyl, haloC 1-6 alkyl; When ring A is When R 1 is ethyl or is replaced by one or more R a Substituted methyl or ethyl.

2. The compound according to claim 1, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, wherein: R 1 is selected from methyl and ethyl; the methyl and ethyl groups are unsubstituted or substituted with 1, 2 or 3 identical or different R a replace; Preferably, each R a are each independently selected from halogen, C 1-4 Alkoxy, -NR'R", halogenated C 1-4 Alkoxy; wherein R' and R" are each independently selected from H, C 1-4 Alkyl, C 3-5 Cycloalkyl, or R' and R" together with the N atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, S; Preferably, each R a are each independently selected from halogen, C 5-6 Alkoxy, -NR'R", halogenated C 5-6 Alkoxy; wherein R' and R" are each independently selected from H, C 5-6 Alkyl, C 5-6 Cycloalkyl, or R' and R" together with the N atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, S; Preferably, each R a are each independently selected from halogen, C 1-3 Alkoxy, -NR'R", halogenated C 1-3 Alkoxy; wherein R' and R" are each independently selected from H, C 1-3 Alkyl, C 3-4 Cycloalkyl, or R' and R" together with the N atom to which they are attached form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, S; Preferably, each R a Each is independently selected from halogen, methoxy, ethoxy, propoxy, -NR'R", halogenated methoxy, halogenated ethoxy, halogenated propoxy; wherein R' and R" are independently selected from H, methyl, ethyl, or R' and R" together with the N atom to which they are connected form a 4-8 membered nitrogen-containing heterocyclic group; the 4-8 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, S; Preferably, each R a Each is independently selected from F, Cl, Br, methoxy, ethoxy, propoxy, -NR'R", halomethoxy, haloethoxy, halopropoxy; wherein R' and R" are independently selected from H, methyl, ethyl, or R' and R" together with the N atom to which they are attached form a 4-7 membered nitrogen-containing heterocyclic group, and the 4-7 membered nitrogen-containing heterocyclic group may further contain 1-2 heteroatoms selected from N, O, and S; Preferably, each R a Each independently selected from F, Cl, Br, methoxy, ethoxy, -NR'R", methoxy or ethoxy substituted by 1-3 F or Cl; wherein R' and R" are each independently selected from methyl, Ethyl, or R' and R" together with the N atom to which they are attached form a 4-7 membered nitrogen-containing heterocyclic group, which may further contain 1-2 heteroatoms selected from N, O, and S; Preferably, each R a Each independently selected from F, Cl, methoxy, ethoxy, -NR'R", -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3; wherein R' and R" are each independently selected from methyl, ethyl, or R' and R" together with the N atom to which they are connected form Preferably, each R a Each independently selected from F, Cl, methoxy, N,N-dimethylamino, N-methylamino, -OCHF2, Preferably, R 1 Selected from methyl, ethyl, -CH2CH2F, -CH2CHF2, -CH2CH2Cl, methoxyethyl, Preferably, when ring A is When R 1 is ethyl or -CH2CH2F; Preferably, R 1 Selected from methyl and ethyl, wherein the methyl and ethyl are unsubstituted.

3. The compound according to claim 1, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, wherein: Ring A is selected from C 4-7 Monocyclic alkyl, C 5-10 Spirobicycloalkyl, 4-7 membered monoheterocyclic group or 6-10 membered spirobicycloalkyl; the 4-7 membered monoheterocyclic group or 6-10 membered spirobicycloalkyl contains 1 to 4 heteroatoms selected from N, O, S, the C 4-7 Monocyclic alkyl, C 5-10 The spiro bicycloalkyl, 4-7 membered monoheterocyclic group, 6-10 membered spiro bicycloheterocyclic group is unsubstituted or substituted by 1, 2 or 3 identical or different R b replace; Ring A is selected from C 4-6 Monocyclic alkyl, C 6-8 Spirobicycloalkyl, 4-7 membered monoheterocyclic group or 6-8 membered spirobicycloalkyl, wherein the 4-7 membered monoheterocyclic group or 6-8 membered spirobicycloalkyl contains 1 to 2 heteroatoms selected from N, O, S, and the C 4-6 Monocyclic alkyl, C 6-8 The spiro bicycloalkyl, 4-7 membered monoheterocyclic group, 6-8 membered spiro bicycloheterocyclic group is unsubstituted or substituted by 1, 2 or 3 identical or different R b replace; Preferably, ring A is selected from Said is unsubstituted or substituted with 1, 2 or 3 identical or different R b replace; Preferably, each R b are each independently selected from halogen, C 1-6 alkyl; Preferably, each R b Each independently selected from F, Cl, Br, C 1-4 Alkyl, C 5-6 alkyl; Preferably, each R b Each is independently selected from F, Cl, Br, methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl; Preferably, each R b Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl; Preferably, each R b Each is independently selected from F, Cl, Br, methyl; Preferably, each R b Each independently selected from F; Preferably, ring A is selected from 4. The compound according to claim 1, or a stereoisomer, tautomer, polymorph, cocrystal, solvate, metabolite, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof, wherein: In A1, R 4 Selected from F, Cl, C 1-4 Alkyl, C 5-6 Alkyl, haloC 1-4 Alkyl, haloC 5-6 alkyl; Preferably, in A1, R 4 Selected from F, Cl, C 1-4 Alkyl, haloC 1-4 alkyl; Preferably, in A1, R 4 Selected from F, Cl, methyl, ethyl, propyl, isopropyl, C 1-4 Alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4alkyl; Preferably, in A1, R 4 is selected from F, Cl, methyl, ethyl, fluoro or chloro substituted methyl, fluoro or chloro substituted ethyl; Preferably, in A1, R 4 Selected from F, Cl, methyl; or, In A2, R 5 Selected from F, Cl, Br, C 1-4 Alkyl, C 5-6 Alkyl, haloC 1-4 Alkyl, haloC 5- 6 alkyl; Preferably, in A2, R 5 Selected from F, Cl, Br, C 1-4 Alkyl, haloC 1-4 alkyl; Preferably, in A2, R 5 Selected from F, Cl, Br, C 5-6 Alkyl, haloC 5-6 alkyl; Preferably, in A2, R 5 Selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl; Preferably, in A2, R 5 is selected from F, Cl, Br, methyl, ethyl, fluoro or chloro substituted methyl, fluoro or chloro substituted ethyl; Preferably, in A2, R 5 Selected from F, Cl, Br, methyl; Preferably, in A2, R 5 Selected from F; or, In A3, R 4 and R 5 are each independently selected from halogen, C 1-4 Alkyl, C 5-6 Alkyl, haloC 1-4 Alkyl, haloC 5-6 alkyl; Preferably, in A3, R 4 and R 5 Each independently selected from F, Cl, Br, C 1-4 Alkyl, haloC 1-4 alkyl; Preferably, in A3, R 4 and R 5 Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl; Preferably, in A3, R 4 and R 5 Each is independently selected from F, Cl, Br, methyl, ethyl, fluoro or chloro substituted methyl, fluoro or chloro substituted ethyl; Preferably, in A3, R 4 and R 5 Each independently selected from F or Cl; Preferably, in A3, R 4 For F, R 5 is F or Cl; or, A4, R 6 Selected from F or Cl, R 4 and R 5 are each independently selected from halogen, C 1-4 Alkyl, C 5-6 Alkyl, haloC 1-4 Alkyl, haloC 5-6 Alkyl, when R 6 When it is Cl, R 1 is methyl or ethyl; Preferably, in A4, R 6 Selected from F or Cl, R 4 and R 5 Each independently selected from F, Cl, Br, C 1- 4 Alkyl, halo C 1-4 Alkyl; when R 6 When it is Cl, R 1 is methyl or ethyl; Preferably, in A4, R 6 Selected from F or Cl, R 4 and R 5 Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl; when R 6 When it is Cl, R 1 is methyl or ethyl; Preferably, in A4, R 6 Selected from F or Cl, R 4 and R 5 are each independently selected from F, Cl, Br, methyl, ethyl, methyl substituted with fluorine or chlorine, ethyl substituted with fluorine or chlorine; when R 6 When it is Cl, R 1 is methyl or ethyl; Preferably, in A4, R 6 Selected from F or Cl, R 4 and R 5 Each independently selected from F or Cl; when R 6 When it is Cl, R 1 is methyl or ethyl; or, A5, R 5 and R 6 are each independently selected from halogen, C 1-4 Alkyl, C 5-6 Alkyl, haloC 1-4 Alkyl, haloC 5-6 alkyl; Preferably, in A5, R 5 and R 6 Each independently selected from F, Cl, Br, C 1-4 Alkyl, haloC 1-4 alkyl; Preferably, in A5, R 5 and R 6 Each is independently selected from F, Cl, Br, methyl, ethyl, propyl, isopropyl, C4 alkyl, halomethyl, haloethyl, halopropyl, haloisopropyl, haloC4 alkyl; Preferably, in A5, R 5 and R 6 Each is independently selected from F, Cl, Br, methyl, ethyl, fluoro or chloro substituted methyl, fluoro or chloro substituted ethyl; Preferably, in A5, R 5 and R 6 Each independently selected from F or Cl; Preferably, ring A is selected from When ring A is selected from When R 1 is methyl or ethyl; Preferably, ring A is selected from 5. The compound according to claim 1, or a stereoisomer, tautomer, polymorph, cocrystal, solvate, metabolite, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof, wherein: R 2 and R 3 are each independently selected from H, halogen, C 1-4 Alkyl, C 5-6 alkyl; Preferably, R 2 and R 3 Each is independently selected from H, F, Cl, Br, methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl; Preferably, R 2 and R 3 Each independently selected from H, F, Cl, Br; Preferably, R 2 and R 3 Each independently selected from H, F; Preferably, R 2 and R 3 At the same time, it is H; Or preferably, R 2 and R 3 One of them is H and the other is F; Preferably, R 2 For H, R 3 is F; Or preferably, R 2 For F, R 3 For H.

6. The compound according to any one of claims 1 to 5, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, wherein the compound is selected from:

7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, and optional pharmaceutically acceptable carriers and / or adjuvants and / or diluents.

8. Use of the compound according to any one of claims 1 to 6, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, or the pharmaceutical composition according to claim 7, in the preparation of a medicament for treating and / or preventing diseases associated with Aurora B kinase; Preferably, the disease associated with Aurora B kinase is selected from tumors or hyperproliferative diseases.

9. A method for treating and / or preventing a disease associated with Aurora B kinase, comprising administering to an individual in need thereof a therapeutically and / or prophylactically effective amount of the compound of any one of claims 1 to 6, or its stereoisomers, tautomers, polymorphs, cocrystals, solvates, metabolites, prodrugs, deuterated compounds, pharmaceutically acceptable salts, or the pharmaceutical composition of claim 7; Preferably, the disease associated with Aurora B kinase is selected from tumors or hyperproliferative diseases.

10. The compound according to any one of claims 1 to 6, or its stereoisomer, tautomer, polymorph, cocrystal, solvate, metabolite, prodrug, deuterated compound, pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 7, for use in treating and / or preventing diseases associated with Aurora B kinase; Preferably, the disease associated with Aurora B kinase is selected from tumors or hyperproliferative diseases.